quaternary nitrogen compound - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	quaternary nitrogen compound	go back to main search page
Accession:	CHEBI:26469	browse the term
Definition:	A nitrogen molecular entity that is electronically neutral but which contains a quaternary nitrogen.

show annotations for term's descendants Sort by:
Rat (876) Mouse (910) Human (928) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (34) Green Monkey (0) Naked Mole-rat (0) All
Genes (876)

(R)-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

decreases expression

Carnitine results in decreased expression of ACACA protein

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

decreases expression

Carnitine results in decreased expression of ACACB protein

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

adiponectin, C1Q and collagen domain containing

increases expression

Carnitine results in increased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2 associated X, apoptosis regulator

decreases expression
multiple interactions

Carnitine results in decreased expression of BAX protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA]; Carnitine inhibits the reaction [Methotrexate results in increased expression of BAX protein]

PMID:29186614 PMID:36282381 PMID:37312617

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

gamma-butyrobetaine hydroxylase 1

multiple interactions
increases chemical synthesis

Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]

NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458

G

BCL2, apoptosis regulator

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]

PMID:23213347 PMID:29186614 PMID:36282381 PMID:37312617

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

caspase 3

multiple interactions
increases expression

Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of CASP3 protein]
Carnitine results in increased expression of CASP3 protein
Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein]

PMID:19491382 PMID:23213347 PMID:25669660 PMID:26562095 PMID:32478940 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA]
Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein]

PMID:23213347 PMID:32478940

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA]

PMID:16889571 PMID:19294768 PMID:23213347

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

multiple interactions

Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cadherin 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

collagen type I alpha 1 chain

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of COL1A1 mRNA]

PMID:26581635 PMID:28973641

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

carnitine palmitoyltransferase 1A

multiple interactions

valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine]
[Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein]

PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

multiple interactions
increases expression

Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate]
Carnitine results in increased expression of CPT2 protein

PMID:21816645 PMID:25669660

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cytochrome b-245 beta chain

multiple interactions

Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

fatty acid binding protein 3

multiple interactions

Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA]

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

fatty acid binding protein 9

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein]

NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873

G

fatty acid synthase

decreases expression

Carnitine results in decreased expression of FASN protein

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

follicle stimulating hormone subunit beta

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

growth differentiation factor 9

multiple interactions
increases expression

Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GDF9 mRNA]
Carnitine results in increased expression of GDF9 mRNA

NCBI chr10:37,589,200...37,599,970
Ensembl chr10:37,595,679...37,599,672

G

glial fibrillary acidic protein

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gap junction protein, alpha 1

multiple interactions
increases expression

Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA1 mRNA]
Carnitine results in increased expression of GJA1 mRNA

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, alpha 4

increases expression
multiple interactions

Carnitine results in increased expression of GJA4 mRNA
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA4 mRNA]

NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925

G

glutamic--pyruvic transaminase

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

multiple interactions

Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein]

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

hyaluronan synthase 2

multiple interactions
increases expression

Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of HAS2 mRNA]
Carnitine results in increased expression of HAS2 mRNA

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

heme oxygenase 1

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

harakiri, BCL2 interacting protein

multiple interactions

Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein]

NCBI chr12:38,387,484...38,409,652

G

heat shock protein family A (Hsp70) member 2

multiple interactions

Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein]

NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 10

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA]

PMID:26581635 PMID:33965443

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

increases expression

Carnitine results in increased expression of IL18 protein

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions
increases expression

Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA]
Carnitine results in increased expression of IL1B protein

PMID:25669660 PMID:26562095 PMID:26581635

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Methotrexate results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA]

PMID:26581635 PMID:33965443 PMID:37312617

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

decreases uptake
multiple interactions

INS1 protein results in decreased uptake of Carnitine
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein]

PMID:28298333 PMID:30256492

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

lactate dehydrogenase A

multiple interactions

Carnitine inhibits the reaction [Doxorubicin results in increased activity of LDHA protein]

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

leptin receptor

affects abundance

LEPR affects the abundance of Carnitine

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

luteinizing hormone subunit beta

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

matrix metallopeptidase 9

multiple interactions

Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions
increases activity

[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein]

PMID:18597074 PMID:18852009

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrially encoded cytochrome c oxidase I

multiple interactions

Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA]

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

multiple interactions

Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA]

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

microsomal triglyceride transfer protein

multiple interactions

Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA]

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

NFE2 like bZIP transcription factor 2

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 3

increases expression

Carnitine results in increased expression of NLRP3 protein

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA]

PMID:23213347 PMID:33965443

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

increases expression

Carnitine results in increased expression of NOS3

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

occludin

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein]

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

peroxisome proliferator activated receptor alpha

multiple interactions
increases expression
increases activity

[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins]
Carnitine results in increased expression of PPARA protein
Carnitine results in increased activity of PPARA protein

PMID:19491382 PMID:19735737 PMID:25669660

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

increases expression
multiple interactions

Carnitine results in increased expression of PPARG protein
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of PPARGC1A protein]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

prostaglandin I2 synthase

increases expression
increases response to substance
multiple interactions

Carnitine results in increased expression of PTGIS mRNA
PTGIS protein results in increased susceptibility to Carnitine
[Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha

NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451

G

PYD and CARD domain containing

increases expression

Carnitine results in increased expression of PYCARD protein

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

stearoyl-CoA desaturase

decreases expression

Carnitine results in decreased expression of SCD protein

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

sirtuin 1

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 3

multiple interactions

Carnitine inhibits the reaction [Cyclophosphamide results in increased expression of SIRT3 mRNA]

NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808

G

solute carrier family 22 member 1

decreases expression

Carnitine results in decreased expression of SLC22A1 protein

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 2

decreases expression

Carnitine results in decreased expression of SLC22A2 protein

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 22 (organic cation transporter), member 21

multiple interactions
increases uptake

[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]

NCBI chr10:38,104,114...38,133,106
Ensembl chr10:38,104,122...38,130,671

G

solute carrier family 22 member 4

increases uptake
decreases expression

SLC22A4 protein results in increased uptake of Carnitine
Carnitine results in decreased expression of SLC22A4 protein

PMID:21256917 PMID:25669660 PMID:33007874

NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720

G

solute carrier family 22 member 5

multiple interactions
affects expression
decreases expression
increases transport
increases uptake
increases expression
affects uptake
affects binding

[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
Carnitine affects the expression of SLC22A5 protein
Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin]
Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
Carnitine deficiency results in increased expression of SLC22A5 mRNA
SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog
SLC22A5 protein affects the uptake of Carnitine
Carnitine binds to SLC22A5 protein

PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 More...

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 22 member 8

increases transport

SLC22A8 protein results in increased transport of Carnitine

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 25 member 20

multiple interactions
increases transport

Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

PMID:18452908 PMID:23402788

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

solute carrier family 2 member 4

increases expression
multiple interactions

Carnitine results in increased expression of SLC2A4 protein
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein]

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

snail family transcriptional repressor 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein]

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

sterol regulatory element binding transcription factor 1

multiple interactions
decreases expression

Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA]
Carnitine results in decreased expression of SREBF1 protein

PMID:18299183 PMID:25669660

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

steroidogenic acute regulatory protein

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

transforming growth factor, beta 1

multiple interactions

Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA]

PMID:26562095 PMID:26581635 PMID:28973641

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

multiple interactions

Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tight junction protein 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

increases expression
multiple interactions
decreases expression

Carnitine deficiency results in increased expression of TNF mRNA
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of TNF protein]
Carnitine results in decreased expression of TNF protein

PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vimentin

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

1,1-dimethyl-4-phenylpiperazinium iodide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein]

CTD
RGD

PMID:9454827 PMID:15016836

NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein]

CTD
RGD

PMID:9454827 PMID:15016836

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein]

CTD
RGD

PMID:9454827 PMID:14645658 PMID:15016836

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions
increases response to substance
increases activity

Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]
CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide
Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein

PMID:10082212 PMID:10216184

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein]

CTD
RGD

PMID:14645658 PMID:15016836

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

tumor necrosis factor

increases activity

TNF results in increased activity of Dimethylphenylpiperazinium Iodide

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

1,2-dihexadecanoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 6

multiple interactions

1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

prion protein

multiple interactions
affects folding

Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form]

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

1-O-oleoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

SMAD family member 3

decreases abundance

SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

1-O-palmitoyl-2-O-(5-oxovaleryl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

arachidonate 5-lipoxygenase

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

C-C motif chemokine receptor 2

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

Cd68 molecule

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

C-reactive protein

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

gap junction protein, alpha 1

multiple interactions
increases phosphorylation

AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

interleukin 1 alpha

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

potassium voltage-gated channel subfamily A regulatory beta subunit 2

multiple interactions

[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine

NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

oxidized low density lipoprotein receptor 1

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

platelet-activating factor receptor

affects binding
multiple interactions

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 1

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin E

increases expression
increases secretion

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions
increases phosphorylation

resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

TIMP metallopeptidase inhibitor 4

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA

NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558

G

tumor necrosis factor

increases expression
increases secretion

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase G, endothelial type

increases hydrolysis

LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

1-stearoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

2-acetyl-1-alkyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

increases expression

Platelet Activating Factor results in increased expression of AGTR1 mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

arachidonate 12-lipoxygenase, 12S type

increases expression

Platelet Activating Factor results in increased expression of ALOX12 mRNA

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

arachidonate 5-lipoxygenase

multiple interactions
increases expression

[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor]
Platelet Activating Factor results in increased expression of ALOX5 mRNA

PMID:8387780 PMID:10779545 PMID:16386258

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

C-C motif chemokine ligand 2

multiple interactions
increases secretion

Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine receptor 2

increases expression

Platelet Activating Factor results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-reactive protein

increases expression

Platelet Activating Factor results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

C-X3-C motif chemokine receptor 1

increases expression

Platelet Activating Factor results in increased expression of CX3CR1 mRNA

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

endothelin 1

multiple interactions
increases abundance

Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type B

multiple interactions

EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

early growth response 1

increases expression

Platelet Activating Factor results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

glucuronidase, beta

multiple interactions

[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein]

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

interleukin 1 alpha

increases expression

Platelet Activating Factor results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression
increases secretion
multiple interactions

Platelet Activating Factor results in increased expression of IL1B mRNA
Platelet Activating Factor results in increased secretion of IL1B protein
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]

PMID:16386258 PMID:32830409

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases secretion

[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha M

multiple interactions
increases expression

Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]

PMID:9762784 PMID:11116075

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

leukotriene B4 receptor

affects response to substance

LTB4R1 protein affects the susceptibility to Platelet Activating Factor

NCBI chr15:29,263,199...29,265,716

G

matrix metallopeptidase 13

increases expression

Platelet Activating Factor results in increased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

MYD88, innate immune signal transduction adaptor

increases expression
multiple interactions

Platelet Activating Factor results in increased expression of MYD88 protein
PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

neutral cholesterol ester hydrolase 1

multiple interactions

NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]

NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588

G

NFKB inhibitor alpha

multiple interactions
increases degradation

Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

oxidized low density lipoprotein receptor 1

increases expression

Platelet Activating Factor results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

phospholipase A2 group VII

multiple interactions
increases expression

[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA]

NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476

G

peroxisome proliferator activated receptor alpha

decreases expression

Platelet Activating Factor results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

platelet-activating factor receptor

multiple interactions
increases expression
increases phosphorylation
affects binding

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]
Platelet Activating Factor results in increased expression of PTAFR mRNA
Platelet Activating Factor results in increased phosphorylation of PTAFR protein
bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]

PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 More...

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 1

increases expression

Platelet Activating Factor results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

increases expression

Platelet Activating Factor results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

Pvt1 oncogene

increases expression
multiple interactions

Platelet Activating Factor results in increased expression of PVT1 mRNA
[Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]

NCBI chr 7:93,656,528...93,879,938

G

regulator of G-protein signaling 4

multiple interactions

RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

G

selectin E

increases expression

Platelet Activating Factor results in increased expression of SELE mRNA

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selectin L

multiple interactions
increases secretion

Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

selectin P

multiple interactions
increases expression

Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein]

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

TIMP metallopeptidase inhibitor 4

increases expression

Platelet Activating Factor results in increased expression of TIMP4 mRNA

NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558

G

tumor necrosis factor

increases secretion
multiple interactions
increases expression

Platelet Activating Factor results in increased secretion of TNF protein
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]
TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]
Platelet Activating Factor results in increased expression of TNF mRNA
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]

PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

increases expression

platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma

RGD

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

3-dehydrocarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

4-(trimethylammonio)butanoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gamma-butyrobetaine hydroxylase 1

multiple interactions

[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine

NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

4-DAMP methiodide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor, muscarinic 3

affects binding

4-DAMP methiodide inhibits response to acetylcholine in rat aortic rings

RGD

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

ambenonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

Ambenonium Chloride results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

amyloid beta precursor protein

affects cleavage

Ambenonium Chloride affects the cleavage of APP protein

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

benzalkonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

increases expression

Benzalkonium Compounds results in increased expression of AACS mRNA

NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954

G

ATP binding cassette subfamily A member 1

decreases expression

Benzalkonium Compounds results in decreased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily A member 12

increases expression

Benzalkonium Compounds results in increased expression of ABCA12 mRNA

NCBI chr 9:72,822,661...72,995,748
Ensembl chr 9:72,823,350...72,996,049

G

ATP binding cassette subfamily A member 6

decreases expression

Benzalkonium Compounds results in decreased expression of ABCA6 mRNA

NCBI chr10:95,142,805...95,212,087
Ensembl chr10:95,142,966...95,211,530

G

aconitate decarboxylase 1

increases expression

Benzalkonium Compounds results in increased expression of ACOD1 mRNA

NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529

G

acid phosphatase 6, lysophosphatidic

increases expression

Benzalkonium Compounds results in increased expression of ACP6 mRNA

NCBI chr 2:184,711,975...184,733,067
Ensembl chr 2:184,711,619...184,733,017

G

acyl-CoA synthetase long-chain family member 4

increases expression

Benzalkonium Compounds results in increased expression of ACSL4 mRNA

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

adenosine deaminase

increases expression

Benzalkonium Compounds results in increased expression of ADA mRNA

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

decreases expression

Benzalkonium Compounds results in decreased expression of ADH1 mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

adenosine A1 receptor

decreases expression

Benzalkonium Compounds results in decreased expression of ADORA1 mRNA

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adrenoceptor alpha 2A

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

angiotensin II receptor, type 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

aldo-keto reductase family 1 member B10

increases expression

Benzalkonium Compounds results in increased expression of AKR1B10 mRNA

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

albumin

decreases expression

Benzalkonium Compounds results in decreased expression of ALB mRNA

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

adhesion molecule with Ig like domain 2

increases expression

Benzalkonium Compounds results in increased expression of AMIGO2 mRNA

NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695

G

apolipoprotein A1

decreases expression

Benzalkonium Compounds results in decreased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A2

decreases expression

Benzalkonium Compounds results in decreased expression of APOA2 mRNA

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein C1

decreases expression

Benzalkonium Compounds results in decreased expression of APOC1 mRNA

NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375

G

aquaporin 3 (Gill blood group)

increases expression

Benzalkonium Compounds results in increased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

amphiregulin

increases expression

Benzalkonium Compounds results in increased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

arginase 2

increases expression

Benzalkonium Compounds results in increased expression of ARG2 mRNA

NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378

G

ADP-ribosyltransferase 3

decreases expression

Benzalkonium Compounds results in decreased expression of ART3 mRNA

NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407

G

activating transcription factor 4

decreases expression

Benzalkonium Compounds results in decreased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

ATP synthase F1 subunit epsilon

decreases expression

Benzalkonium Compounds results in decreased expression of ATP5F1E mRNA

NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450

G

ATP synthase membrane subunit G

decreases expression

Benzalkonium Compounds results in decreased expression of ATP5MG mRNA

NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559

G

Beta-1,3-galactosyltransferase 4

affects response to substance

B3GALT4 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,936,089...4,937,664
Ensembl chr20:4,931,768...4,938,315

G

BMP and activin membrane-bound inhibitor

increases expression

Benzalkonium Compounds results in increased expression of BAMBI mRNA

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

BCL3, transcription coactivator

increases expression

Benzalkonium Compounds results in increased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

betacellulin

decreases expression

Benzalkonium Compounds results in decreased expression of BTC mRNA

NCBI chr14:16,708,447...16,746,961
Ensembl chr14:16,707,982...16,747,049

G

complement C3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

caspase 3

increases cleavage
multiple interactions

Benzalkonium Compounds analog results in increased cleavage of CASP3 protein
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

decreases expression

Benzalkonium Compounds results in decreased expression of CASP8 mRNA

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

C-C motif chemokine ligand 11

increases expression

Benzalkonium Compounds results in increased expression of CCL11 protein

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

increases expression
increases secretion

Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein
Benzalkonium Compounds results in increased secretion of CCL2 protein

PMID:30171875 PMID:30517752 PMID:31707104

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression

Benzalkonium Compounds results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 24

decreases expression

Benzalkonium Compounds results in decreased expression of CCL24 mRNA

NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CCL3 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein

PMID:30517752 PMID:31158415

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

decreases expression
multiple interactions
increases expression

Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein
Benzalkonium Compounds results in increased expression of CCL4 protein

PMID:18353026 PMID:20713136 PMID:30517752 PMID:31158415

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

increases expression

Benzalkonium Compounds results in increased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 7

increases expression

Benzalkonium Compounds results in increased expression of CCL7 mRNA; Benzalkonium Compounds results in increased expression of CCL7 protein

PMID:30171875 PMID:30517752

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

cellular communication network factor 2

decreases expression

Benzalkonium Compounds results in decreased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cellular communication network factor 3

increases expression

Benzalkonium Compounds results in increased expression of CCN3 mRNA

NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019

G

C-C motif chemokine receptor 4

decreases expression

Benzalkonium Compounds results in decreased expression of CCR4 mRNA

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056

G

C-C motif chemokine receptor 5

increases expression

Benzalkonium Compounds results in increased expression of CCR5 mRNA

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD177 molecule

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA

NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621

G

CD274 molecule

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD300C molecule 2

increases expression

Benzalkonium Compounds results in increased expression of CD300C2 mRNA

NCBI chr10:100,253,312...100,258,553
Ensembl chr10:100,253,624...100,258,323

G

cell division cycle 6

multiple interactions
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Benzalkonium Compounds results in decreased expression of CDC6 protein]
Benzalkonium Compounds results in decreased expression of CDC6 mRNA; Benzalkonium Compounds results in decreased expression of CDC6 protein

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cilia and flagella associated protein 61

increases expression

Benzalkonium Compounds results in increased expression of CFAP61 mRNA

NCBI chr 3:133,354,400...133,633,310
Ensembl chr 3:133,354,197...133,633,320

G

complement factor D

decreases expression

Benzalkonium Compounds results in decreased expression of CFD mRNA

NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053

G

chitinase 3 like 1

increases expression

Benzalkonium Compounds results in increased expression of CHI3L1 mRNA

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

cholinergic receptor nicotinic beta 4 subunit

decreases expression

Benzalkonium Compounds results in decreased expression of CHRNB4 mRNA

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

CIMAP1 family member D

decreases expression

Benzalkonium Compounds results in decreased expression of CIMAP1D mRNA

NCBI chr 7:10,049,472...10,065,626
Ensembl chr 7:10,059,589...10,065,125

G

cardiotrophin-like cytokine factor 1

increases expression

Benzalkonium Compounds results in increased expression of CLCF1 mRNA

NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605

G

cornifelin

increases expression

Benzalkonium Compounds results in increased expression of CNFN mRNA; Benzalkonium Compounds results in increased expression of CNFN protein

NCBI chr 1:80,949,699...80,953,747
Ensembl chr 1:80,951,600...80,953,747

G

colony stimulating factor 1

increases expression

Benzalkonium Compounds results in increased expression of CSF1 protein

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 2

increases expression

Benzalkonium Compounds results in increased expression of CSF2 protein

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 3

increases expression

Benzalkonium Compounds results in increased expression of CSF3 protein

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

CTP synthase 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA

NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180

G

C-X-C motif chemokine ligand 10

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein

PMID:23445166 PMID:30517752 PMID:31158415

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 2

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein

PMID:30171875 PMID:30517752 PMID:31158415

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions
increases expression

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA
Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA

PMID:30171875 PMID:30517752

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine ligand 6

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CXCL5 mRNA; Benzalkonium Compounds results in increased expression of CXCL5 protein
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA

PMID:30171875 PMID:30517752

NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093

G

C-X-C motif chemokine receptor 1

increases expression

Benzalkonium Compounds results in increased expression of CXCR1 mRNA

NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084

G

C-X-C motif chemokine receptor 4

increases expression

Benzalkonium Compounds results in increased expression of CXCR4 mRNA

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases expression
increases expression

Benzalkonium Compounds results in decreased expression of CYP1A1 mRNA
Benzalkonium Compounds results in increased expression of CYP1A1 mRNA

PMID:20713136 PMID:30806763

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

Benzalkonium Compounds results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 51

increases expression

Benzalkonium Compounds results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

DNA-damage inducible transcript 3

increases expression

Benzalkonium Compounds results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

24-dehydrocholesterol reductase

increases expression

Benzalkonium Compounds results in increased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

decreases activity
increases expression

Benzalkonium Compounds results in decreased activity of DHCR7 protein
Benzalkonium Compounds results in increased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

iodothyronine deiodinase 1

decreases activity

Benzalkonium Compounds results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

decreases activity

Benzalkonium Compounds results in decreased activity of DIO2 protein

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

decreases activity

Benzalkonium Compounds results in decreased activity of DIO3 protein

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

delta like non-canonical Notch ligand 1

decreases expression

Benzalkonium Compounds results in decreased expression of DLK1 mRNA

NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522

G

dual specificity phosphatase 1

increases expression

Benzalkonium Compounds results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 10

increases expression

Benzalkonium Compounds results in increased expression of DUSP10 mRNA

NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716

G

EBP, cholestenol delta-isomerase

increases expression

Benzalkonium Compounds results in increased expression of EBP mRNA

NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826

G

epidermal growth factor

decreases expression

Benzalkonium Compounds results in decreased expression of EGF mRNA

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

early growth response 1

increases expression

Benzalkonium Compounds results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

E74 like ETS transcription factor 3

increases expression

Benzalkonium Compounds results in increased expression of ELF3 mRNA

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

ELOVL fatty acid elongase 1

increases expression

Benzalkonium Compounds results in increased expression of ELOVL1 mRNA

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

ELOVL fatty acid elongase 6

increases expression

Benzalkonium Compounds results in increased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

endonuclease, poly(U)-specific

increases expression

Benzalkonium Compounds results in increased expression of ENDOU mRNA

NCBI chr 7:128,844,872...128,866,572
Ensembl chr 7:128,844,862...128,866,596

G

enolase 1

decreases expression

Benzalkonium Compounds results in decreased expression of ENO1 mRNA

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

ethanolamine kinase 1

increases expression

Benzalkonium Compounds results in increased expression of ETNK1 mRNA

NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770

G

exonuclease 1

increases expression

Benzalkonium Compounds results in increased expression of EXO1 mRNA

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654

G

ezrin

increases expression

Benzalkonium Compounds results in increased expression of EZR mRNA; Benzalkonium Compounds results in increased expression of EZR protein

NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505

G

family with sequence similarity 83, member A

increases expression

Benzalkonium Compounds results in increased expression of FAM83A mRNA

NCBI chr 7:89,522,826...89,547,284
Ensembl chr 7:89,522,826...89,547,388

G

fibroblast growth factor 2

affects response to substance

FGF2 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

FGR proto-oncogene, Src family tyrosine kinase

increases expression

Benzalkonium Compounds results in increased expression of FGR mRNA

NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326

G

filaggrin

increases expression

Benzalkonium Compounds results in increased expression of FLG mRNA

NCBI chr 2:178,884,793...178,912,986

G

forkhead box C1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA

NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803

G

forkhead box N1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA

NCBI chr10:63,251,400...63,273,710
Ensembl chr10:63,251,400...63,273,710

G

forkhead box P3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

GATA binding protein 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Benzalkonium Compounds results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression

Benzalkonium Compounds results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glutathione peroxidase 2

increases expression

Benzalkonium Compounds results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

heparin-binding EGF-like growth factor

increases expression

Benzalkonium Compounds results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

HCK proto-oncogene, Src family tyrosine kinase

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA

NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

Benzalkonium Compounds results in increased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

hepatocyte growth factor

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

increases expression

Benzalkonium Compounds results in increased expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

Benzalkonium Compounds results in increased expression of HMGCR mRNA

PMID:26919959 PMID:31199489

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

increases expression

Benzalkonium Compounds results in increased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression

Benzalkonium Compounds results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homeobox A7

decreases expression

Benzalkonium Compounds results in decreased expression of HOXA7 mRNA

NCBI chr 4:81,315,730...81,317,629
Ensembl chr 4:81,314,625...81,317,659

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

Benzalkonium Compounds results in increased expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

heat shock protein family A (Hsp70) member 5

decreases expression

Benzalkonium Compounds results in decreased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

increases expression

Benzalkonium Compounds results in increased expression of ICAM1 mRNA; Benzalkonium Compounds results in increased expression of ICAM1 protein

PMID:21742781 PMID:30806763

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

increases expression

Benzalkonium Compounds results in increased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

isopentenyl-diphosphate delta isomerase 1

increases expression

Benzalkonium Compounds results in increased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon gamma

increases expression

Benzalkonium Compounds results in increased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions
increases expression

Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein
Benzalkonium Compounds results in increased expression of IL10 protein

PMID:29953848 PMID:30517752 PMID:31158415

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13 receptor subunit alpha 2

increases expression

Benzalkonium Compounds results in increased expression of IL13RA2 mRNA

NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381

G

interleukin 15

increases expression

Benzalkonium Compounds results in increased expression of IL15 protein

NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820

G

interleukin 17F

increases expression

Benzalkonium Compounds results in increased expression of IL17F mRNA

NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482

G

interleukin 18

increases expression

Benzalkonium Compounds results in increased expression of IL18 protein
Benzalkonium Compounds results in increased expression of IL18 mRNA

PMID:30517752 PMID:30806763

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

increases secretion
multiple interactions
increases expression

Benzalkonium Compounds results in increased secretion of IL1A protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein
Benzalkonium Compounds results in increased expression of IL1A protein
Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein

PMID:8006454 PMID:12781210 PMID:25290854 PMID:30240708 PMID:30517752 More...

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of IL1B protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein

PMID:29953848 PMID:30517752 PMID:31158415

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 family member 10

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA

NCBI chr 3:7,072,511...7,075,439
Ensembl chr 3:7,072,511...7,075,439

G

interleukin 23 subunit alpha

increases expression

Benzalkonium Compounds results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 24

increases expression

Benzalkonium Compounds results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 27

increases expression

Benzalkonium Compounds results in increased expression of IL27 protein

NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582

G

interleukin 3

increases expression

Benzalkonium Compounds results in increased expression of IL3 protein

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 31

increases expression

Benzalkonium Compounds results in increased expression of IL31 protein

NCBI chr12:33,095,108...33,105,026
Ensembl chr12:33,092,097...33,105,037

G

interleukin 31 receptor A

decreases expression

Benzalkonium Compounds results in decreased expression of IL31RA mRNA

NCBI chr 2:44,118,748...44,189,943
Ensembl chr 2:44,122,624...44,183,767

G

interleukin 34

decreases expression

Benzalkonium Compounds results in decreased expression of IL34 mRNA

NCBI chr19:38,714,990...38,782,749
Ensembl chr19:38,714,991...38,764,000

G

interleukin 36, alpha

increases expression

Benzalkonium Compounds results in increased expression of IL36A mRNA

NCBI chr 3:6,996,851...7,001,400
Ensembl chr 3:6,996,851...7,001,400

G

interleukin 36, beta

increases expression

Benzalkonium Compounds results in increased expression of IL36B mRNA

NCBI chr 3:7,024,881...7,030,388
Ensembl chr 3:7,021,973...7,031,619

G

interleukin 36, gamma

increases expression

Benzalkonium Compounds results in increased expression of IL36G mRNA

NCBI chr 3:6,948,323...6,954,485
Ensembl chr 3:6,948,297...6,954,480

G

interleukin 4

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of IL4 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein

PMID:30517752 PMID:31158415

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

increases expression

Benzalkonium Compounds results in increased expression of IL5 protein

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

increases secretion
multiple interactions
affects response to substance
increases expression

Benzalkonium Compounds results in increased secretion of IL6 protein
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein
Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein
Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein

PMID:17763283 PMID:28214551 PMID:29953848 PMID:30171875 PMID:30517752 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 receptor

multiple interactions
increases response to substance

[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

interleukin 7 receptor

increases expression

Benzalkonium Compounds results in increased expression of IL7R mRNA

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

inhibin subunit beta A

increases expression

Benzalkonium Compounds results in increased expression of INHBA mRNA

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

insulin induced gene 1

increases expression

Benzalkonium Compounds results in increased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

ISL LIM homeobox 1

decreases expression

Benzalkonium Compounds results in decreased expression of ISL1 mRNA

NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584

G

iodotyrosine deiodinase

multiple interactions

Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Benzalkonium Compounds results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

lysine demethylase 7A

increases expression

Benzalkonium Compounds results in increased expression of KDM7A mRNA

NCBI chr 4:67,899,407...67,974,264
Ensembl chr 4:67,904,307...67,966,998

G

lysine demethylase 8

decreases expression

Benzalkonium Compounds results in decreased expression of KDM8 mRNA

NCBI chr 1:180,013,969...180,028,829
Ensembl chr 1:180,020,656...180,028,841

G

KLF transcription factor 2

increases expression

Benzalkonium Compounds results in increased expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

kallikrein related-peptidase 8

increases expression

Benzalkonium Compounds results in increased expression of KLK8 mRNA

NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646

G

keratin 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA

NCBI chr 7:132,940,879...132,948,031
Ensembl chr 7:132,940,862...132,947,963

G

keratin associated protein 14

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA

NCBI chr11:28,126,660...28,127,502
Ensembl chr11:28,126,660...28,127,502

G

late cornified envelope 1M

decreases expression

Benzalkonium Compounds results in decreased expression of LCE1M mRNA

NCBI chr 2:178,637,495...178,638,697
Ensembl chr 2:178,637,495...178,638,697

G

late cornified envelope 3E

increases expression

Benzalkonium Compounds results in increased expression of LCE3C mRNA

NCBI chr 2:178,578,488...178,579,661
Ensembl chr 2:178,579,162...178,579,458

G

lactate dehydrogenase A

decreases expression

Benzalkonium Compounds results in decreased expression of LDHA mRNA

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

low density lipoprotein receptor

increases expression

Benzalkonium Compounds results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

LIF, interleukin 6 family cytokine

increases expression

Benzalkonium Compounds results in increased expression of LIF protein

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

U6 spliceosomal RNA

decreases expression

Benzalkonium Compounds results in decreased expression of RNU6-643P

NCBI chr15:99,491,045...99,491,148
Ensembl chr15:99,491,045...99,491,148

G

small nucleolar RNA SNORA71

decreases expression

Benzalkonium Compounds results in decreased expression of SNORA71D mRNA

NCBI chr 1:232,131,169...232,131,300
Ensembl chr 1:232,131,169...232,131,300

G

lysyl oxidase-like 1

decreases expression

Benzalkonium Compounds results in decreased expression of LOXL1 mRNA

NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356

G

leukocyte specific transcript 1

increases expression

Benzalkonium Compounds results in increased expression of LST1 mRNA

NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997

G

lymphotoxin beta

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA

NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381

G

mitogen activated protein kinase 14

increases phosphorylation

Benzalkonium Compounds results in increased phosphorylation of MAPK14 protein

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mesoderm posterior bHLH transcription factor 2

decreases expression

Benzalkonium Compounds results in decreased expression of MESP2 mRNA

NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198

G

macrophage migration inhibitory factor

increases secretion

Benzalkonium Compounds results in increased secretion of MIF protein

NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504

G

matrix metallopeptidase 10

increases expression

Benzalkonium Compounds results in increased expression of MMP10 mRNA

NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748

G

matrix metallopeptidase 12

increases expression

Benzalkonium Compounds results in increased expression of MMP12 mRNA

NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611

G

matrix metallopeptidase 2

increases activity

Benzalkonium Compounds results in increased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 25

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA

NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871

G

matrix metallopeptidase 9

multiple interactions
increases activity

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA
Benzalkonium Compounds results in increased activity of MMP9 protein

PMID:21058936 PMID:30171875

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

methylsterol monooxygenase 1

increases expression

Benzalkonium Compounds results in increased expression of MSMO1 mRNA

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

msh homeobox 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA

NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879

G

metallothionein 2A

decreases expression

Benzalkonium Compounds results in decreased expression of MT2 mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases expression

Benzalkonium Compounds results in decreased expression of MTHFD2 mRNA

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

myosin light chain kinase 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA

NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954

G

Ndufa4, mitochondrial complex associated

decreases expression

Benzalkonium Compounds results in decreased expression of NDUFA4 mRNA

NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920

G

nuclear receptor subfamily 4, group A, member 2

increases expression

Benzalkonium Compounds results in increased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

neuregulin 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA

NCBI chr18:27,616,542...27,798,505
Ensembl chr18:27,619,661...27,798,505

G

neurotrophic receptor tyrosine kinase 3

affects response to substance

NTRK3 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286

G

occludin

decreases expression

Benzalkonium Compounds results in decreased expression of OCLN protein

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

ornithine decarboxylase 1

decreases expression

Benzalkonium Compounds results in decreased expression of ODC1 mRNA

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

oxidized low density lipoprotein receptor 1

increases expression

Benzalkonium Compounds results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

orosomucoid 1

decreases expression

Benzalkonium Compounds results in decreased expression of ORM1 mRNA

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

Benzalkonium Compounds analog results in increased cleavage of PARP1 protein
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

PDZ binding kinase

increases expression

Benzalkonium Compounds results in increased expression of PBK mRNA

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

proprotein convertase subtilisin/kexin type 9

decreases expression

Benzalkonium Compounds results in decreased expression of PCSK9 mRNA

NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688

G

programmed cell death 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA

NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937

G

prefoldin subunit 6

affects response to substance

PFDN6 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,945,959...4,947,433
Ensembl chr20:4,945,959...4,947,433

G

peptidoglycan recognition protein 3

increases expression

Benzalkonium Compounds results in increased expression of PGLYRP3 mRNA

NCBI chr 2:177,479,693...177,490,769
Ensembl chr 2:177,477,407...177,490,736
Ensembl chr 2:177,477,407...177,490,736

G

phosphoglycolate phosphatase

increases expression

Benzalkonium Compounds results in increased expression of PGP mRNA

NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858

G

phospholipase A2, group V

decreases expression

Benzalkonium Compounds results in decreased expression of PLA2G5 mRNA

NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658

G

phosphatidylinositol-specific phospholipase C, X domain containing 3

increases expression

Benzalkonium Compounds results in increased expression of PLCXD3 mRNA

NCBI chr 2:53,567,022...53,746,384
Ensembl chr 2:53,567,022...53,746,384

G

polo-like kinase 2

decreases expression

Benzalkonium Compounds results in decreased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

patatin-like phospholipase domain containing 2

decreases expression

Benzalkonium Compounds results in decreased expression of PNPLA2 mRNA

NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805

G

RNA polymerase I and III subunit D

decreases expression

Benzalkonium Compounds results in decreased expression of POLR1D mRNA

NCBI chr12:7,970,592...8,004,157
Ensembl chr12:7,970,595...8,005,624

G

peroxisome proliferator activated receptor alpha

decreases expression

Benzalkonium Compounds results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein kinase AMP-activated catalytic subunit alpha 2

increases expression

Benzalkonium Compounds results in increased expression of PRKAA2 mRNA

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

G

protein kinase AMP-activated non-catalytic subunit gamma 2

increases expression

Benzalkonium Compounds results in increased expression of PRKAG2 mRNA

NCBI chr 4:10,010,890...10,252,155
Ensembl chr 4:10,010,890...10,252,142

G

prokineticin receptor 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA

NCBI chr 3:119,624,738...119,639,442
Ensembl chr 3:119,627,601...119,635,718

G

prostaglandin-endoperoxide synthase 2

increases expression

Benzalkonium Compounds results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

pentraxin 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

ral guanine nucleotide dissociation stimulator like 2

affects response to substance

RGL2 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,948,495...4,956,774
Ensembl chr20:4,948,497...4,969,911

G

regenerating family member 1 alpha

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA

NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570

G

regenerating family member 3 gamma

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA

NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723

G

ribosomal protein S18

affects response to substance

RPS18 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,931,427...4,935,538
Ensembl chr10:101,204,500...101,205,146
Ensembl chr20:101,204,500...101,205,146

G

RT1 class II, locus DOa

affects response to substance

HLA-DOA SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577

G

RT1 class II, locus DOb

affects response to substance

HLA-DOB SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667

G

RT1 class II, locus Ha

affects response to substance

HLA-DPA1 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244

G

RT1 class II, locus Hb, pseudogene 1

affects response to substance

HLA-DPB1 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618

G

ryanodine receptor 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

stearoyl-CoA desaturase

increases expression
decreases expression

Benzalkonium Compounds results in increased expression of SCD mRNA
Benzalkonium Compounds results in decreased expression of SCD1 mRNA

PMID:29155129 PMID:31199489

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

serpin family B member 13

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA

NCBI chr13:23,118,582...23,150,352
Ensembl chr13:23,118,584...23,150,760

G

serpin family E member 1

increases expression

Benzalkonium Compounds results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

sestrin 2

decreases expression

Benzalkonium Compounds results in decreased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

stratifin

increases expression

Benzalkonium Compounds results in increased expression of SFN mRNA

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

secreted frizzled-related protein 4

decreases expression

Benzalkonium Compounds results in decreased expression of SFRP4 mRNA

NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736

G

solute carrier family 16 member 1

increases expression

Benzalkonium Compounds results in increased expression of SLC16A1 mRNA

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

solute carrier family 7 member 11

increases expression

Benzalkonium Compounds results in increased expression of SLC7A11 mRNA

PMID:30806763 PMID:37149095

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

small nucleolar RNA, H/ACA box 38

decreases expression

Benzalkonium Compounds results in decreased expression of SNORA38

NCBI chr20:3,660,900...3,661,033
Ensembl chr20:3,660,900...3,661,033

G

SRY-box transcription factor 21

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA

NCBI chr15:95,292,429...95,296,024
Ensembl chr15:95,292,265...95,296,091

G

small proline-rich protein 1A

increases expression

Benzalkonium Compounds results in increased expression of SPRR1A mRNA

NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063

G

small proline-rich protein 1B

increases expression

Benzalkonium Compounds results in increased expression of SPRR1B mRNA

NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567

G

small proline rich protein 2A

increases expression

Benzalkonium Compounds results in increased expression of SPRR2H mRNA

NCBI chr 2:177,815,964...177,816,236
Ensembl chr 2:177,815,964...177,816,236

G

small proline rich protein 2B

increases expression

Benzalkonium Compounds results in increased expression of SPRR2B mRNA

NCBI chr 2:177,852,824...177,853,096
Ensembl chr 2:177,852,824...177,853,096

G

small proline rich protein 2F

increases expression

Benzalkonium Compounds results in increased expression of SPRR2F mRNA

NCBI chr 2:177,989,974...177,990,204
Ensembl chr 2:177,989,974...177,990,204

G

squalene epoxidase

increases expression

Benzalkonium Compounds results in increased expression of SQLE mRNA

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

sterol regulatory element binding transcription factor 2

increases expression

Benzalkonium Compounds results in increased expression of SREBF2 mRNA

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA

NCBI chr 3:168,318,511...168,324,915
Ensembl chr 3:168,318,512...168,324,915

G

ST14 transmembrane serine protease matriptase

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA

NCBI chr 8:29,540,805...29,581,704
Ensembl chr 8:29,540,811...29,581,517

G

TAP binding protein

affects response to substance

TAPBP SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,956,937...4,966,191
Ensembl chr20:4,956,937...4,966,181

G

transcription factor AP-2 beta

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA

NCBI chr 9:21,786,251...21,816,054
Ensembl chr 9:21,786,258...21,814,520

G

transforming growth factor, beta 1

increases expression

Benzalkonium Compounds results in increased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transglutaminase 3

increases expression

Benzalkonium Compounds results in increased expression of TGM3 mRNA

NCBI chr 3:117,228,661...117,264,078
Ensembl chr 3:117,228,661...117,264,075

G

transglutaminase 7

decreases expression

Benzalkonium Compounds results in decreased expression of TGM7 mRNA

NCBI chr 3:108,051,890...108,068,116
Ensembl chr 3:108,051,890...108,076,239

G

thrombospondin 1

increases expression

Benzalkonium Compounds results in increased expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

toll-like receptor 1

increases expression

Benzalkonium Compounds results in increased expression of TLR1 mRNA

NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125

G

toll-like receptor 4

increases activity

Benzalkonium Compounds results in increased activity of TLR4 protein

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

transmembrane serine protease 11B

increases expression

Benzalkonium Compounds results in increased expression of TMPRSS11B mRNA

NCBI chr14:21,383,936...21,407,283
Ensembl chr14:21,383,862...21,408,817

G

tumor necrosis factor

decreases secretion
increases expression

Benzalkonium Compounds results in decreased secretion of TNF protein
Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein

PMID:29953848 PMID:30171875 PMID:30517752

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 6

increases expression

Benzalkonium Compounds results in increased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

TNF receptor superfamily member 13C

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA

NCBI chr 7:113,736,046...113,738,523
Ensembl chr 7:113,736,055...113,738,517

G

TNF receptor superfamily member 9

increases expression

Benzalkonium Compounds results in increased expression of TNFRSF9 mRNA

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

TNF superfamily member 8

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA

NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421

G

tumor protein p53

decreases expression

Benzalkonium Compounds results in decreased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

triosephosphate isomerase 1

decreases expression

Benzalkonium Compounds results in decreased expression of TPI1 mRNA

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

triggering receptor expressed on myeloid cells 2

increases expression

Benzalkonium Compounds results in increased expression of TREM2 mRNA

NCBI chr 9:12,647,605...12,654,190
Ensembl chr 9:12,647,259...12,654,170

G

tribbles pseudokinase 3

increases expression

Benzalkonium Compounds results in increased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

thymic stromal lymphopoietin

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA

NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548

G

UL16 binding protein 1

increases expression

Benzalkonium Compounds results in increased expression of ULBP1 mRNA

NCBI chr 1:1,694,255...1,716,160

G

uroplakin 3B

decreases expression

Benzalkonium Compounds results in decreased expression of UPK3B mRNA

NCBI chr12:20,630,231...20,637,634
Ensembl chr12:20,631,525...20,637,724

G

ubiquinol-cytochrome c reductase, complex III subunit VII

decreases expression

Benzalkonium Compounds results in decreased expression of UQCRQ mRNA

NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169

G

vascular endothelial growth factor D

increases expression

Benzalkonium Compounds results in increased expression of VEGFD mRNA

NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295

G

V-set domain containing T cell activation inhibitor 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA

NCBI chr 2:188,253,594...188,321,658
Ensembl chr 2:188,253,594...188,321,658

G

WD repeat domain 46

affects response to substance

WDR46 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,937,845...4,945,796
Ensembl chr20:4,937,847...4,946,535

G

X-box binding protein 1

decreases expression

Benzalkonium Compounds results in decreased expression of XBP1 mRNA alternative form

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

X-C motif chemokine ligand 1

decreases expression

Benzalkonium Compounds results in decreased expression of XCL1 mRNA

NCBI chr13:77,248,687...77,252,343
Ensembl chr13:77,248,717...77,252,329

benzethonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 1 family, member L2

increases expression

Benzethonium results in increased expression of ALDH1L2 mRNA

NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776

G

arrestin domain containing 4

decreases expression

Benzethonium results in decreased expression of ARRDC4 mRNA

NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

Benzethonium results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

C-C motif chemokine ligand 2

decreases expression

Benzethonium results in decreased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

decreases expression

Benzethonium results in decreased expression of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

decreases expression

Benzethonium results in decreased expression of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

decreases expression

Benzethonium results in decreased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

increases expression

Benzethonium results in increased expression of CHAC1 mRNA

NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526

G

DNA-damage inducible transcript 3

increases expression

Benzethonium results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4

increases expression

Benzethonium results in increased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

Benzethonium results in increased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

interferon gamma

multiple interactions

[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

immunoglobulin heavy constant gamma 1

decreases expression

Benzethonium results in decreased expression of IGHG1 mRNA

Ensembl chr 6:132,389,370...132,393,397

G

interleukin 1 beta

decreases expression

Benzethonium results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 6 receptor

decreases expression

Benzethonium results in decreased expression of IL6R protein modified form

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

insulin induced gene 1

increases expression

Benzethonium results in increased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

potassium voltage-gated channel subfamily A member 3

decreases activity
multiple interactions

Benzethonium results in decreased activity of KCNA3 protein
[Benzethonium results in decreased activity of KCNA3 protein] which results in decreased import of Thallium

NCBI chr 2:194,632,106...194,634,059
Ensembl chr 2:194,632,196...194,650,138

G

potassium voltage-gated channel subfamily H member 2

multiple interactions
decreases activity

[Benzethonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium

PMID:21362439 PMID:23313619 PMID:24052561

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

low density lipoprotein receptor

increases expression

Benzethonium results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

U6 spliceosomal RNA

increases expression

Benzethonium results in increased expression of RNU6-1014P

NCBI chr 4:102,735,624...102,735,728
Ensembl chr 4:102,735,624...102,735,728

G

nuclear receptor subfamily 4, group A, member 2

increases expression

Benzethonium results in increased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

phosphoserine aminotransferase 1

increases expression

Benzethonium results in increased expression of PSAT1 mRNA

NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682

G

RNA, U6 small nuclear 767

decreases expression

Benzethonium results in decreased expression of RNU6-767P

NCBI chr 2:102,241,494...102,241,597
Ensembl chr 2:102,241,494...102,241,597

G

sestrin 2

increases expression

Benzethonium results in increased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

solute carrier family 22 member 2

multiple interactions

Benzethonium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 7 member 11

increases expression

Benzethonium results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

vascular endothelial growth factor A

decreases expression

Benzethonium results in decreased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

bretylium tosylate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 2

multiple interactions

Bretylium Tosylate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

butylscopolamine bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 2

multiple interactions

Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

CAR(3:0(Me2))

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 5

affects binding
increases uptake
multiple interactions
increases transport

pivaloylcarnitine binds to SLC22A5 protein
SLC22A5 protein results in increased uptake of pivaloylcarnitine
Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]

PMID:18762717 PMID:19539806

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase beta

decreases expression

L-carnitine decreases expression of Acacb mRNA and protein in rat heart

RGD

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

carnitine palmitoyltransferase 1A

increases expression
multiple interactions

L-carnitine increases expression of Cpt1a mRNA and protein in rat heart
L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

malonyl-CoA decarboxylase

increases expression
multiple interactions

L-carnitine increases expression of Mlycd protein in rat heart
L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

protein kinase AMP-activated catalytic subunit alpha 2

increases expression
multiple interactions

L-carnitine increases expression of Ampka2 protein in rat serum and heart
L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

ceftaroline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

defensin beta 5

multiple interactions

Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of and results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of DEFB4A protein]

PMID:27397760 PMID:28720485

NCBI chr16:70,612,985...70,615,389
Ensembl chr16:70,613,146...70,615,467

G

interleukin 1 beta

multiple interactions

Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

toll-like receptor 2

multiple interactions

Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR2 protein]

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

multiple interactions

Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in increased secretion of TNF protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

chlormequat chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 1700009N14 gene like

increases expression

Chlormequat results in increased expression of 1700009N14RIKL protein

NCBI chr 5:54,456,005...54,457,381
Ensembl chr 5:54,455,893...54,457,677

G

ATP binding cassette subfamily D member 1

increases expression

Chlormequat results in increased expression of ABCD1 protein

NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115

G

adenosine deaminase, RNA-specific, B1

decreases expression

Chlormequat results in decreased expression of ADARB1 protein

NCBI chr20:11,222,569...11,350,854
Ensembl chr20:11,222,583...11,350,852

G

angiotensin II receptor-associated protein

increases expression

Chlormequat results in increased expression of AGTRAP protein

NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036

G

aryl hydrocarbon receptor

multiple interactions

Chlormequat promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

ALG12, alpha-1,6-mannosyltransferase

decreases expression

Chlormequat results in decreased expression of ALG12 protein

NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458

G

ALG14, UDP-N-acetylglucosaminyltransferase subunit

decreases expression

Chlormequat results in decreased expression of ALG14 protein

NCBI chr 2:209,368,285...209,445,425
Ensembl chr 2:209,368,312...209,445,431

G

apolipoprotein L9a

increases expression

Chlormequat results in increased expression of APOL9A protein

NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649

G

Rho GTPase activating protein 20

increases expression

Chlormequat results in increased expression of ARHGAP20 protein

NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739

G

atlastin GTPase 1

increases expression

Chlormequat results in increased expression of ATL1 protein

NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204

G

ATPase phospholipid transporting 10B

increases expression

Chlormequat results in increased expression of ATP10B protein

NCBI chr10:27,495,207...27,751,313
Ensembl chr10:27,408,747...27,749,637

G

B9 domain containing 2

increases expression

Chlormequat results in increased expression of B9D2 protein

NCBI chr 1:81,189,395...81,195,383
Ensembl chr 1:81,189,405...81,195,356

G

Bet1 golgi vesicular membrane trafficking protein-like

increases expression

Chlormequat results in increased expression of BET1L protein

NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040

G

bone gamma-carboxyglutamate protein

decreases expression

Chlormequat results in decreased expression of BGLAP protein

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

complement C1q C chain

increases expression

Chlormequat results in increased expression of C1QC protein

NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017

G

caspase activity and apoptosis inhibitor 1

decreases expression

Chlormequat results in decreased expression of CAAP1 protein

NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314

G

chromobox 1

increases expression

Chlormequat results in increased expression of CBX1 protein

NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096

G

coiled-coil domain containing 32

increases expression

Chlormequat results in increased expression of CCDC32 protein

NCBI chr 3:105,998,429...106,010,985
Ensembl chr 3:105,998,430...106,010,975

G

cyclin Y-like 1

increases expression

Chlormequat results in increased expression of CCNYL1 protein

NCBI chr 9:66,071,721...66,121,742
Ensembl chr 9:66,071,543...66,107,999

G

copper chaperone for superoxide dismutase

increases expression

Chlormequat results in increased expression of CCS protein

NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915

G

CD151 molecule (Raph blood group)

decreases expression

Chlormequat results in decreased expression of CD151 protein

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

CD55 molecule (Cromer blood group)

increases expression

Chlormequat results in increased expression of CD55 protein

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

cilia and flagella associated protein 298

increases expression

Chlormequat results in increased expression of CFAP298 protein

NCBI chr11:30,181,916...30,191,302
Ensembl chr11:30,181,905...30,191,346

G

charged multivesicular body protein 7

increases expression

Chlormequat results in increased expression of CHMP7 protein

NCBI chr15:44,790,983...44,806,216
Ensembl chr15:44,790,996...44,806,216

G

coordinator of PRMT5 and differentiation stimulator

increases expression

Chlormequat results in increased expression of COPRS protein

NCBI chr16:75,721,264...75,726,375
Ensembl chr16:75,720,061...75,726,375

G

coenzyme Q4

increases expression

Chlormequat results in increased expression of COQ4 protein

NCBI chr 3:13,060,054...13,070,502
Ensembl chr 3:13,060,455...13,068,799

G

casein kinase 1, alpha 1

increases expression

Chlormequat results in increased expression of CSNK1A1 protein

NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271

G

cathepsin S

decreases expression

Chlormequat results in decreased expression of CTSS protein

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

Chlormequat results in decreased expression of CYP11A1 protein

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450 family 7 subfamily A member 1

increases expression

Chlormequat results in increased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

death-associated protein

decreases expression

Chlormequat results in decreased expression of DAP protein

NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752

G

DDB1 and CUL4 associated factor 13

increases expression

Chlormequat results in increased expression of DCAF13 protein

NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142

G

dynactin subunit 6

increases expression

Chlormequat results in increased expression of DCTN6 protein

NCBI chr16:58,077,595...58,096,604
Ensembl chr16:58,077,585...58,096,968

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

delta(4)-desaturase, sphingolipid 1

increases expression

Chlormequat results in increased expression of DEGS1 protein

NCBI chr13:93,946,154...93,953,677
Ensembl chr13:93,946,157...93,953,664

G

DnaJ heat shock protein family (Hsp40) member C14

increases expression

Chlormequat results in increased expression of DNAJC14 protein

NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645

G

dynamin binding protein

increases expression

Chlormequat results in increased expression of DNMBP protein

NCBI chr 1:242,736,189...242,829,431
Ensembl chr 1:242,736,189...242,802,604

G

dynein light chain Tctex-type 3

increases expression

Chlormequat results in increased expression of DYNLT3 protein

NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139

G

glutamyl-tRNA synthetase 2, mitochondrial

increases expression

Chlormequat results in increased expression of EARS2 protein

NCBI chr 1:176,597,986...176,625,848
Ensembl chr 1:176,597,986...176,625,836

G

eukaryotic translation elongation factor 1 alpha 2

decreases expression

Chlormequat results in decreased expression of EEF1A2 protein

NCBI chr 3:168,265,893...168,275,071
Ensembl chr 3:168,195,357...168,275,071

G

ELOVL fatty acid elongase 1

increases expression

Chlormequat results in increased expression of ELOVL1 protein

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

ELOVL fatty acid elongase 5

increases expression

Chlormequat results in increased expression of ELOVL5 protein

NCBI chr 8:78,790,846...78,857,307
Ensembl chr 8:78,790,846...78,857,284

G

enolase 3

decreases expression

Chlormequat results in decreased expression of ENO3 protein

NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921

G

EvC ciliary complex subunit 1

increases expression

Chlormequat results in increased expression of EVC protein

NCBI chr14:73,456,181...73,498,955
Ensembl chr14:73,456,222...73,498,099

G

fatty acid binding protein 4

decreases expression

Chlormequat results in decreased expression of FABP4 protein

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

FA complementation group D2

decreases expression

Chlormequat results in decreased expression of FANCD2 protein

NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412

G

fibulin 1

increases expression

Chlormequat results in increased expression of FBLN1 protein

NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression

Chlormequat results in decreased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box K2

decreases expression

Chlormequat results in decreased expression of FOXK2 protein

NCBI chr10:106,542,643...106,592,569
Ensembl chr10:106,542,566...106,592,563

G

GABA type A receptor-associated protein

increases expression

Chlormequat results in increased expression of GABARAP protein

NCBI chr10:54,714,777...54,718,099
Ensembl chr10:54,714,198...54,717,765

G

growth hormone 1

increases expression

Chlormequat results in increased expression of GH1 protein

PMID:31704167 PMID:32622971

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

growth hormone receptor

decreases expression

Chlormequat results in decreased expression of GHR mRNA

NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735

G

growth hormone releasing hormone

increases expression

Chlormequat results in increased expression of GHRH protein

NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889

G

G protein subunit alpha i1

increases expression

Chlormequat results in increased expression of GNAI1 protein

NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417

G

G protein subunit gamma 5

decreases expression

Chlormequat results in decreased expression of GNG5 protein

NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513

G

gonadotropin releasing hormone 1

increases expression

Chlormequat results in increased expression of GNRH1 protein

NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581

G

glutathione S-transferase alpha 2

increases expression

Chlormequat results in increased expression of GSTA2 protein

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

general transcription factor IIH subunit 5

increases expression

Chlormequat results in increased expression of GTF2H5 protein

NCBI chr 1:46,656,804...46,663,512
Ensembl chr 1:46,656,859...46,664,939

G

H1.0 linker histone

increases expression

Chlormequat results in increased expression of H1-0 protein

NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694

G

H1.5 linker histone, cluster member

increases expression

Chlormequat results in increased expression of H1-5 protein

NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160

G

heme binding protein 2

increases expression

Chlormequat results in increased expression of HEBP2 protein

NCBI chr 1:13,194,982...13,201,777
Ensembl chr 1:13,194,982...13,201,777

G

HERPUD family member 2

increases expression

Chlormequat results in increased expression of HERPUD2 protein

NCBI chr 8:23,573,374...23,618,380
Ensembl chr 8:23,573,379...23,617,874

G

heterogeneous nuclear ribonucleoprotein C

increases expression

Chlormequat results in increased expression of HNRNPC protein

NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

decreases expression

Chlormequat results in decreased expression of HSD3B1 protein

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

insulin-like growth factor 1

affects expression
increases expression

Chlormequat affects the expression of IGF1 protein
Chlormequat results in increased expression of IGF1 protein

PMID:28214531 PMID:31704167

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

internexin neuronal intermediate filament protein, alpha

decreases expression

Chlormequat results in decreased expression of INA protein

NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330

G

isochorismatase domain containing 2b

increases expression

Chlormequat results in increased expression of ISOC2 protein

NCBI chr 1:68,972,960...68,993,760
Ensembl chr 1:68,972,960...68,993,757

G

integrin subunit beta 1 binding protein 1

increases expression

Chlormequat results in increased expression of ITGB1BP1 protein

NCBI chr 6:40,820,693...40,836,074
Ensembl chr 6:40,821,339...40,836,037

G

kazrin, periplakin interacting protein

increases expression

Chlormequat results in increased expression of KAZN protein

NCBI chr 5:154,392,793...155,381,567
Ensembl chr 5:154,392,793...154,779,074

G

kelch-like family member 26

decreases expression

Chlormequat results in decreased expression of KLHL26 protein

NCBI chr16:18,952,123...18,977,328
Ensembl chr16:18,952,234...18,977,328

G

kelch-like family member 7

decreases expression

Chlormequat results in decreased expression of KLHL7 protein

NCBI chr 4:11,006,366...11,055,399
Ensembl chr 4:11,006,375...11,055,541

G

LIM domain binding 1

increases expression

Chlormequat results in increased expression of LDB1 protein

NCBI chr 1:244,864,168...244,890,007
Ensembl chr 1:244,877,173...244,890,013

G

luteinizing hormone subunit beta

increases expression

Chlormequat results in increased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

leucine rich repeat containing 7

increases expression

Chlormequat results in increased expression of LRRC7 protein

NCBI chr 2:247,146,616...247,634,945
Ensembl chr 2:247,147,752...247,634,547

G

macroH2A.1 histone

increases expression

Chlormequat results in increased expression of MACROH2A1 protein

NCBI chr17:8,479,331...8,542,071
Ensembl chr17:8,479,372...8,542,072

G

macroH2A.2 histone

increases expression

Chlormequat results in increased expression of MACROH2A2 protein

NCBI chr20:29,678,194...29,727,867
Ensembl chr20:29,678,222...29,727,891

G

microtubule-associated protein 4

decreases expression

Chlormequat results in decreased expression of MAP4 protein

NCBI chr 8:109,925,233...110,064,370
Ensembl chr 8:109,925,575...110,064,362

G

alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B

increases expression

Chlormequat results in increased expression of MGAT4B protein

NCBI chr10:34,548,918...34,559,229
Ensembl chr10:34,549,433...34,559,229

G

motile sperm domain containing 3

decreases expression

Chlormequat results in decreased expression of MOSPD3 protein

NCBI chr12:19,095,203...19,100,303
Ensembl chr12:19,095,242...19,099,477

G

Mov10 RNA helicase

increases expression

Chlormequat results in increased expression of MOV10 protein

NCBI chr 2:192,292,041...192,315,142
Ensembl chr 2:192,293,470...192,315,083

G

MAGUK p55 scaffold protein 2

decreases expression

Chlormequat results in decreased expression of MPP2 protein

NCBI chr10:87,011,434...87,043,883
Ensembl chr10:87,011,434...87,043,896

G

MPV17 mitochondrial inner membrane protein like 2

increases expression

Chlormequat results in increased expression of MPV17L2 protein

NCBI chr16:18,680,106...18,684,212
Ensembl chr16:18,681,826...18,684,212

G

mitochondrial ribosomal protein L51

increases expression

Chlormequat results in increased expression of MRPL51 protein

NCBI chr 4:157,991,756...157,994,715
Ensembl chr 4:157,992,408...157,995,414

G

mitochondrial ribosomal protein L54

increases expression

Chlormequat results in increased expression of MRPL54 protein

NCBI chr 7:8,452,801...8,455,321
Ensembl chr 7:8,452,716...8,455,321

G

mitochondrial ribosomal protein S14

increases expression

Chlormequat results in increased expression of MRPS14 protein

NCBI chr13:72,429,168...72,434,915
Ensembl chr13:72,408,558...72,434,915

G

mitochondrial translation release factor in rescue

increases expression

Chlormequat results in increased expression of MTRFR protein

NCBI chr12:32,261,569...32,275,258
Ensembl chr12:32,258,435...32,275,258

G

nucleolin

increases expression

Chlormequat results in increased expression of NCL protein

NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136

G

NHP2 ribonucleoprotein

increases expression

Chlormequat results in increased expression of NHP2 protein

NCBI chr10:35,877,057...35,880,399
Ensembl chr10:35,877,054...35,882,545

G

NIPA magnesium transporter 1

decreases expression

Chlormequat results in decreased expression of NIPA1 protein

NCBI chr 1:106,834,000...106,875,148
Ensembl chr 1:106,834,000...106,874,790

G

natriuretic peptide receptor 3

decreases expression

Chlormequat results in decreased expression of NPR3 protein

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

nuclear receptor subfamily 3, group C, member 2

increases expression

Chlormequat results in increased expression of NR3C2 protein

NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885

G

ORAI calcium release-activated calcium modulator 1

increases expression

Chlormequat results in increased expression of ORAI1 protein

NCBI chr12:33,533,151...33,548,361
Ensembl chr12:33,534,344...33,548,405

G

poly(A) binding protein, cytoplasmic 1

increases expression

Chlormequat results in increased expression of PABPC1 protein

NCBI chr 7:67,777,438...67,789,731
Ensembl chr 7:67,777,381...67,789,744

G

poly(A) binding protein, cytoplasmic 4

increases expression

Chlormequat results in increased expression of PABPC4 protein

NCBI chr 5:135,563,142...135,578,985
Ensembl chr 5:135,563,562...135,578,979

G

propionyl-CoA carboxylase subunit beta

increases expression

Chlormequat results in increased expression of PCCB protein

NCBI chr 8:101,591,218...101,641,213
Ensembl chr 8:101,590,737...101,641,234

G

peroxisomal biogenesis factor 26

increases expression

Chlormequat results in increased expression of PEX26 protein

NCBI chr 4:154,414,332...154,426,954
Ensembl chr 4:154,414,849...154,426,952

G

pyroglutamyl-peptidase I

increases expression

Chlormequat results in increased expression of PGPEP1 protein

NCBI chr16:18,770,563...18,782,968
Ensembl chr16:18,771,021...18,783,478

G

pleckstrin homology-like domain, family B, member 1

increases expression

Chlormequat results in increased expression of PHLDB1 protein

NCBI chr 8:45,003,543...45,051,541
Ensembl chr 8:45,003,538...45,051,522

G

protein inhibitor of activated STAT, 3

decreases expression

Chlormequat results in decreased expression of PIAS3 protein

NCBI chr 2:184,232,546...184,241,455
Ensembl chr 2:184,232,571...184,241,480

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

increases expression

Chlormequat results in increased expression of PIK3CD protein

NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930

G

phosphatidylinositol transfer protein, membrane-associated 2

increases expression

Chlormequat results in increased expression of PITPNM2 protein

NCBI chr12:32,347,455...32,479,103
Ensembl chr12:32,380,805...32,479,102

G

DNA polymerase epsilon 4, accessory subunit

increases expression

Chlormequat results in increased expression of POLE4 protein

NCBI chr 4:115,165,285...115,171,097
Ensembl chr 4:115,165,285...115,171,097

G

periphilin 1

increases expression

Chlormequat results in increased expression of PPHLN1 protein

NCBI chr 7:124,538,594...124,629,985
Ensembl chr 7:124,538,627...124,629,985

G

protein kinase cAMP-dependent type I regulatory subunit beta

increases expression

Chlormequat results in increased expression of PRKAR1B protein

NCBI chr12:15,492,233...15,624,942
Ensembl chr12:15,511,801...15,624,942

G

proteasome 20S subunit beta 7

increases expression

Chlormequat results in increased expression of PSMB7 protein

NCBI chr 3:22,357,777...22,417,748
Ensembl chr 3:22,354,698...22,417,937

G

RAB6A, member RAS oncogene family

increases expression

Chlormequat results in increased expression of RAB6A protein

NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715

G

RAD17 checkpoint clamp loader component

increases expression

Chlormequat results in increased expression of RAD17 protein

NCBI chr 2:31,764,260...31,794,542
Ensembl chr 2:31,764,261...31,794,072

G

ras homolog family member Q

increases expression

Chlormequat results in increased expression of RHOQ protein

NCBI chr 6:7,613,632...7,652,047

G

ring finger protein 113A1

decreases expression

Chlormequat results in decreased expression of RNF113A1 protein

NCBI chr X:116,427,941...116,429,164
Ensembl chr X:116,427,684...116,433,762

G

ring finger protein 185

increases expression
multiple interactions

Chlormequat results in increased expression of RNF185 protein
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of RNF185 protein]

NCBI chr14:78,292,517...78,329,832
Ensembl chr14:78,292,516...78,329,864

G

ring finger and SPRY domain containing 1

increases expression

Chlormequat results in increased expression of RSPRY1 protein

NCBI chr19:10,352,449...10,403,015
Ensembl chr19:10,353,821...10,401,102

G

reticulon 1

decreases expression

Chlormequat results in decreased expression of RTN1 protein

NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436

G

S100 calcium binding protein A1

increases expression

Chlormequat results in increased expression of S100A1 protein

NCBI chr 2:175,993,922...175,998,765
Ensembl chr 2:175,993,922...175,999,544

G

sterile alpha motif domain containing 8

increases expression

Chlormequat results in increased expression of SAMD8 protein

NCBI chr15:2,512,104...2,562,368
Ensembl chr15:2,512,105...2,515,379
Ensembl chr15:2,512,105...2,515,379

G

secretion associated, Ras related GTPase 1A

increases expression

Chlormequat results in increased expression of SAR1A protein

NCBI chr20:29,623,529...29,635,935
Ensembl chr20:29,623,553...29,635,935

G

shroom family member 1

decreases expression

Chlormequat results in decreased expression of SHROOM1 protein

NCBI chr10:37,621,149...37,631,895
Ensembl chr10:37,621,723...37,631,256

G

Ski proto-oncogene

increases expression

Chlormequat results in increased expression of SKI protein

NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733

G

solute carrier family 48 member 1

decreases expression

Chlormequat results in decreased expression of SLC48A1 protein

NCBI chr 7:128,915,136...128,923,929
Ensembl chr 7:128,915,195...128,923,024

G

slit guidance ligand 3

increases expression

Chlormequat results in increased expression of SLIT3 protein

NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634

G

SLU7 homolog, splicing factor

increases expression

Chlormequat results in increased expression of SLU7 protein

NCBI chr10:27,908,325...27,923,784
Ensembl chr10:27,908,396...27,923,349

G

small integral membrane protein 26

decreases expression

Chlormequat results in decreased expression of SMIM26 protein

NCBI chr 3:131,990,147...131,991,779
Ensembl chr 3:131,990,291...131,992,132

G

SPNS lysolipid transporter 1, lysophospholipid

increases expression

Chlormequat results in increased expression of SPNS1 protein

NCBI chr 1:180,942,088...180,949,415
Ensembl chr 1:180,942,088...180,949,370

G

signal peptide peptidase-like 2B

increases expression

Chlormequat results in increased expression of SPPL2B protein

NCBI chr 7:8,843,918...8,856,642
Ensembl chr 7:8,843,918...8,856,608

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 1

increases expression

Chlormequat results in increased expression of ST3GAL1 protein

NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236

G

suppression of tumorigenicity 7-like

decreases expression

Chlormequat results in decreased expression of ST7L protein

NCBI chr 2:192,364,594...192,434,414
Ensembl chr 2:192,364,594...192,487,190

G

steroidogenic acute regulatory protein

decreases expression

Chlormequat results in decreased expression of STAR protein

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

serine/threonine kinase 26

increases expression

Chlormequat results in increased expression of STK26 protein

NCBI chr X:130,325,064...130,375,674
Ensembl chr X:130,310,885...130,374,291

G

sushi domain containing 2

increases expression

Chlormequat results in increased expression of SUSD2 protein

NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903

G

TATA-box binding protein associated factor 7

increases expression

Chlormequat results in increased expression of TAF7 protein

NCBI chr18:29,459,937...29,462,086
Ensembl chr18:29,452,943...29,462,134

G

TRPM8 channel-associated factor 1

increases expression

Chlormequat results in increased expression of TCAF1 protein

NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309

G

transcription elongation factor A N-terminal and central domain containing

decreases expression

Chlormequat results in decreased expression of TCEANC protein

NCBI chr X:27,952,539...27,961,038
Ensembl chr X:27,952,457...27,960,940

G

terminal nucleotidyltransferase 2

increases expression

Chlormequat results in increased expression of TENT2 protein

NCBI chr 2:24,380,135...24,432,099
Ensembl chr 2:24,380,225...24,432,099

G

thioesterase superfamily member 4

decreases expression

Chlormequat results in decreased expression of THEM4 protein

NCBI chr 2:181,953,550...181,974,708
Ensembl chr 2:181,953,550...181,974,708

G

THO complex subunit 6

increases expression

Chlormequat results in increased expression of THOC6 protein

NCBI chr10:12,700,051...12,705,411
Ensembl chr10:12,700,051...12,706,925

G

TIR domain containing adaptor protein

increases expression

Chlormequat results in increased expression of TIRAP protein

NCBI chr 8:33,531,724...33,548,508
Ensembl chr 8:33,531,725...33,547,432

G

transketolase

increases expression

Chlormequat results in increased expression of TKT protein

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

transmembrane protein 106C

increases expression

Chlormequat results in increased expression of TMEM106C protein

NCBI chr 7:129,088,468...129,094,128
Ensembl chr 7:129,088,498...129,094,130

G

transmembrane protein 184C

decreases expression

Chlormequat results in decreased expression of TMEM184C protein

NCBI chr19:30,345,183...30,361,275
Ensembl chr19:30,345,290...30,361,269

G

transmembrane protein 208

increases expression

Chlormequat results in increased expression of TMEM208 protein

NCBI chr19:33,203,587...33,206,287
Ensembl chr19:33,203,587...33,212,183

G

transmembrane protein 222

increases expression

Chlormequat results in increased expression of TMEM222 protein

NCBI chr 5:145,465,847...145,477,932
Ensembl chr 5:145,465,847...145,484,491

G

TNF superfamily member 11

affects expression

Chlormequat affects the expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

tumor protein p53 inducible protein 11

increases expression

Chlormequat results in increased expression of TP53I11 protein

NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050

G

transformer 2 alpha

increases expression

Chlormequat results in increased expression of TRA2A protein

NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712

G

translocation associated membrane protein 2

decreases expression

Chlormequat results in decreased expression of TRAM2 protein

NCBI chr 9:23,419,204...23,498,745
Ensembl chr 9:23,424,232...23,498,689

G

tetratricopeptide repeat domain 12

increases expression

Chlormequat results in increased expression of TTC12 protein

NCBI chr 8:49,799,916...49,847,940
Ensembl chr 8:49,799,920...49,847,087

G

ubiquitin-conjugating enzyme E2D 1

increases expression
multiple interactions

Chlormequat results in increased expression of UBE2D1 protein
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of UBE2D1 protein]

NCBI chr20:17,309,315...17,343,770
Ensembl chr20:17,309,315...17,342,295

G

uncoupling protein 2

decreases expression

Chlormequat results in decreased expression of UCP2 protein

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

WD repeat domain 74

increases expression

Chlormequat results in increased expression of WDR74 protein

NCBI chr 1:205,631,769...205,636,558
Ensembl chr 1:205,631,824...205,636,563

G

WD repeat and SOCS box-containing 2

decreases expression

Chlormequat results in decreased expression of WSB2 protein

NCBI chr12:39,217,645...39,238,634
Ensembl chr12:39,217,648...39,238,640

G

zinc finger E-box binding homeobox 1

increases expression

Chlormequat results in increased expression of ZEB1 protein

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

colesevelam hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-reactive protein

decreases expression

Colesevelam Hydrochloride results in decreased expression of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
increases expression

Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA]
Colesevelam Hydrochloride results in increased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

low density lipoprotein receptor

increases expression

Colesevelam Hydrochloride results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

Didecyldimethylammonium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 3

increases expression

didecyldimethylammonium results in increased expression of ABCA3 protein

NCBI chr10:13,382,439...13,439,748
Ensembl chr10:13,382,540...13,439,745

G

aldehyde dehydrogenase 1 family, member L2

increases expression

didecyldimethylammonium results in increased expression of ALDH1L2 mRNA

NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776

G

apoptotic peptidase activating factor 1

increases expression

didecyldimethylammonium results in increased expression of APAF1 protein

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

didecyldimethylammonium results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

ATPase plasma membrane Ca2+ transporting 4

decreases expression

didecyldimethylammonium results in decreased expression of ATP2B4 mRNA

NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246

G

bone morphogenetic protein 2

increases expression

didecyldimethylammonium results in increased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 4

decreases expression

didecyldimethylammonium results in decreased expression of BMP4 mRNA

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

bone morphogenetic protein 7

decreases expression

didecyldimethylammonium results in decreased expression of BMP7 mRNA

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

caspase 3

increases cleavage

didecyldimethylammonium results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

collagen and calcium binding EGF domains 1

decreases expression

didecyldimethylammonium results in decreased expression of CCBE1 mRNA

NCBI chr18:59,579,851...59,823,977
Ensembl chr18:59,580,768...59,824,400

G

coiled-coil domain containing 80

decreases expression

didecyldimethylammonium results in decreased expression of CCDC80 mRNA

NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137

G

C-C motif chemokine ligand 2

increases expression

didecyldimethylammonium results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

multiple interactions
increases expression

didecyldimethylammonium results in decreased expression of and results in decreased secretion of CCL3 protein
didecyldimethylammonium results in increased expression of CCL3 protein

PMID:19762220 PMID:32763356

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

increases expression

didecyldimethylammonium results in increased expression of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

increases expression

didecyldimethylammonium results in increased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine receptor 1

increases expression

didecyldimethylammonium results in increased expression of CCR1 mRNA

NCBI chr 8:123,556,286...123,561,841

G

C-C motif chemokine receptor 2

increases expression

didecyldimethylammonium results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 3

decreases expression

didecyldimethylammonium results in decreased expression of CCR3 mRNA

NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990

G

C-C motif chemokine receptor 5

increases expression

didecyldimethylammonium results in increased expression of CCR5 mRNA

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD24 molecule

decreases expression

didecyldimethylammonium results in decreased expression of CD24 mRNA

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

G

CCAAT/enhancer binding protein gamma

increases expression

didecyldimethylammonium results in increased expression of CEBPG mRNA

NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569

G

claudin 1

increases expression

didecyldimethylammonium results in increased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

chloride intracellular channel 4

increases expression

didecyldimethylammonium results in increased expression of CLIC4 protein

NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452

G

collagen type I alpha 1 chain

increases expression
decreases expression

didecyldimethylammonium results in increased expression of COL1A1 mRNA
didecyldimethylammonium results in decreased expression of COL1A1 mRNA

PMID:19762220 PMID:23537712 PMID:32763356

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

increases expression

didecyldimethylammonium results in increased expression of COL1A2 mRNA

PMID:19762220 PMID:23537712

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type VIII alpha 1 chain

decreases expression

didecyldimethylammonium results in decreased expression of COL8A1 mRNA

NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424

G

carboxypeptidase A4

decreases expression

didecyldimethylammonium results in decreased expression of CPA4 mRNA

NCBI chr 4:59,188,284...59,212,255
Ensembl chr 4:59,188,284...59,212,255

G

CREB3 regulatory factor

increases expression

didecyldimethylammonium results in increased expression of CREBRF mRNA

NCBI chr10:16,399,170...16,479,650
Ensembl chr10:16,404,596...16,461,999

G

cysteine-rich secretory protein LCCL domain containing 2

decreases expression

didecyldimethylammonium results in decreased expression of CRISPLD2 mRNA

NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465

G

DNA-damage inducible transcript 3

increases expression

didecyldimethylammonium results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

iodothyronine deiodinase 1

decreases activity

didecyldimethylammonium results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

decreases activity

didecyldimethylammonium results in decreased activity of DIO2 protein

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

decreases activity

didecyldimethylammonium results in decreased activity of DIO3 protein

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

dickkopf WNT signaling pathway inhibitor 1

decreases expression

didecyldimethylammonium results in decreased expression of DKK1 mRNA

NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202

G

DnaJ heat shock protein family (Hsp40) member B9

increases expression

didecyldimethylammonium results in increased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

epidermal growth factor receptor

decreases expression

didecyldimethylammonium results in decreased expression of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

ectodermal-neural cortex 1

decreases expression

didecyldimethylammonium results in decreased expression of ENC1 mRNA

NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713

G

epiregulin

increases expression

didecyldimethylammonium results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

endoplasmic reticulum to nucleus signaling 1

increases expression

didecyldimethylammonium results in increased expression of ERN1 mRNA

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

fibrillarin

decreases expression

didecyldimethylammonium results in decreased expression of FBL protein

NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932

G

FH2 domain containing 1

decreases expression

didecyldimethylammonium results in decreased expression of FHDC1 mRNA

NCBI chr 2:169,790,917...169,829,580
Ensembl chr 2:169,790,947...169,827,896

G

filamin C

decreases expression

didecyldimethylammonium results in decreased expression of FLNC mRNA

NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844

G

growth differentiation factor 15

increases expression

didecyldimethylammonium results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GDNF family receptor alpha 1

decreases expression

didecyldimethylammonium results in decreased expression of GFRA1 mRNA

NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473

G

gap junction protein, alpha 1

decreases expression

didecyldimethylammonium results in decreased expression of GJA1 mRNA

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

didecyldimethylammonium results in increased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

heme oxygenase 1

increases expression

didecyldimethylammonium results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

intercellular adhesion molecule 1

increases expression

didecyldimethylammonium results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inducible T-cell co-stimulator

increases expression

didecyldimethylammonium results in increased expression of ICOS protein

NCBI chr 9:62,368,075...62,406,900
Ensembl chr 9:62,383,832...62,405,672

G

insulin-like growth factor binding protein 3

decreases expression

didecyldimethylammonium results in decreased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

interleukin 10

multiple interactions

didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

increases expression

didecyldimethylammonium results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions

didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL1B protein
didecyldimethylammonium results in increased expression of and results in increased secretion of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

increases expression

didecyldimethylammonium results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 2 receptor subunit alpha

increases expression

didecyldimethylammonium results in increased expression of IL2RA protein

NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697

G

interleukin 4

increases expression
multiple interactions

didecyldimethylammonium results in increased expression of IL4 protein
didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL4 protein

PMID:30649503 PMID:32763356

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

increases expression
multiple interactions

didecyldimethylammonium results in increased expression of IL6 protein
didecyldimethylammonium results in increased expression of IL6 mRNA
didecyldimethylammonium results in increased expression of and results in increased secretion of IL6 protein

PMID:19762220 PMID:32763356

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 7 receptor

decreases expression

didecyldimethylammonium results in decreased expression of IL7R protein

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

inhibin subunit beta B

decreases expression

didecyldimethylammonium results in decreased expression of INHBB mRNA

NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832

G

integrin subunit alpha 2

increases expression

didecyldimethylammonium results in increased expression of ITGA2 mRNA

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

iodotyrosine deiodinase

multiple interactions

didecyldimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

didecyldimethylammonium results in decreased activity of KCNH2 protein
[didecyldimethylammonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium

PMID:21362439 PMID:28551711

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

lysine demethylase 7A

increases expression

didecyldimethylammonium results in increased expression of KDM7A mRNA

NCBI chr 4:67,899,407...67,974,264
Ensembl chr 4:67,904,307...67,966,998

G

KIT proto-oncogene receptor tyrosine kinase

decreases expression

didecyldimethylammonium results in decreased expression of KIT mRNA

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

kelch-like family member 24

increases expression

didecyldimethylammonium results in increased expression of KLHL24 mRNA

NCBI chr11:80,843,621...80,877,649
Ensembl chr11:80,846,755...80,877,636

G

killer cell lectin like receptor G1

increases expression

didecyldimethylammonium results in increased expression of KLRG1 protein

NCBI chr 4:155,455,465...155,467,301
Ensembl chr 4:155,455,495...155,467,424

G

lysosomal-associated membrane protein 2

decreases expression

didecyldimethylammonium results in decreased expression of LAMP2 protein

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

U6 spliceosomal RNA

increases expression

didecyldimethylammonium results in increased expression of RNU6-659P mRNA

NCBI chr14:88,336,534...88,336,640
Ensembl chr14:88,336,534...88,336,640

G

U6 spliceosomal RNA

decreases expression

didecyldimethylammonium results in decreased expression of RNU6-301P mRNA

NCBI chr20:8,850,618...8,850,719
Ensembl chr20:8,850,618...8,850,719

G

leucine rich repeat containing 15

decreases expression

didecyldimethylammonium results in decreased expression of LRRC15 mRNA

NCBI chr11:70,469,817...70,484,268
Ensembl chr11:70,469,804...70,484,267

G

leucine rich adaptor protein 1-like

increases expression

didecyldimethylammonium results in increased expression of LURAP1L mRNA

NCBI chr 5:95,362,005...95,409,439
Ensembl chr 5:95,362,005...95,409,438

G

membrane associated guanylate kinase, WW and PDZ domain containing 2

increases expression

didecyldimethylammonium results in increased expression of MAGI2 mRNA

NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:14,386,399...15,870,240

G

mitogen-activated protein kinase kinase 6

decreases expression

didecyldimethylammonium results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

matrilin 2

decreases expression

didecyldimethylammonium results in decreased expression of MATN2 mRNA

NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113

G

mesoderm specific transcript

decreases expression

didecyldimethylammonium results in decreased expression of MEST mRNA

NCBI chr 4:59,354,445...59,364,919
Ensembl chr 4:59,354,447...59,366,145

G

mitofusin 1

increases expression

didecyldimethylammonium results in increased expression of MFN1 protein

NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640

G

matrix metallopeptidase 1

multiple interactions
increases expression

didecyldimethylammonium results in increased expression of and results in increased secretion of MMP1 protein
didecyldimethylammonium results in increased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

molybdenum cofactor sulfurase

increases expression

didecyldimethylammonium results in increased expression of MOCOS mRNA

NCBI chr18:15,931,659...15,977,415
Ensembl chr18:15,931,654...15,977,187

G

myosin light chain 9

decreases expression

didecyldimethylammonium results in decreased expression of MYL9 mRNA

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

natural killer cell cytotoxicity receptor 3 ligand 1

increases expression

didecyldimethylammonium results in increased expression of NCR3LG1 mRNA

NCBI chr 1:96,565,664...96,581,825
Ensembl chr 1:96,574,455...96,580,466

G

natriuretic peptide receptor 3

decreases expression

didecyldimethylammonium results in decreased expression of NPR3 mRNA

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

neuronal regeneration related protein

decreases expression

didecyldimethylammonium results in decreased expression of NREP mRNA

NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591

G

OPA1, mitochondrial dynamin like GTPase

increases expression

didecyldimethylammonium results in increased expression of OPA1 protein

NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109

G

poly (ADP-ribose) polymerase 1

decreases expression

didecyldimethylammonium results in decreased expression of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

protocadherin beta 8

decreases expression

didecyldimethylammonium results in decreased expression of PCDHB5 mRNA

NCBI chr18:29,065,466...29,067,805
Ensembl chr18:29,065,466...29,067,805

G

phosphodiesterase 1C

decreases expression

didecyldimethylammonium results in decreased expression of PDE1C mRNA

NCBI chr 4:85,300,858...85,777,948
Ensembl chr 4:85,300,858...85,863,219

G

protein phosphatase 1, regulatory subunit 15A

increases expression

didecyldimethylammonium results in increased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

proline rich 16

decreases expression

didecyldimethylammonium results in decreased expression of PRR16 mRNA

NCBI chr18:44,424,348...44,764,796
Ensembl chr18:44,424,616...44,632,329

G

phosphoserine aminotransferase 1

increases expression

didecyldimethylammonium results in increased expression of PSAT1 mRNA

NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682

G

pentraxin 3

increases expression

didecyldimethylammonium results in increased expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

regulator of G-protein signaling 4

decreases expression

didecyldimethylammonium results in decreased expression of RGS4 mRNA

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

G

spermidine/spermine N1-acetyl transferase 1

increases expression

didecyldimethylammonium results in increased expression of SAT1 mRNA

NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813

G

serpin family B member 2

increases expression

didecyldimethylammonium results in increased expression of SERPINB2 mRNA

NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408

G

serpin family E member 1

decreases expression

didecyldimethylammonium results in decreased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

sestrin 2

increases expression

didecyldimethylammonium results in increased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

surfactant protein B

increases expression

didecyldimethylammonium results in increased expression of SFTPB protein

NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436

G

surfactant protein D

increases expression

didecyldimethylammonium results in increased expression of SFTPD protein

NCBI chr16:17,046,491...17,058,968
Ensembl chr16:17,046,483...17,059,927

G

S-phase kinase associated protein 2

decreases expression

didecyldimethylammonium results in decreased expression of SKP2 mRNA

NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338

G

solute carrier family 22, member 15

increases expression

didecyldimethylammonium results in increased expression of SLC22A15 mRNA

NCBI chr 2:189,298,836...189,359,902
Ensembl chr 2:189,298,832...189,358,792

G

solute carrier family 38, member 4

decreases expression

didecyldimethylammonium results in decreased expression of SLC38A4 mRNA

NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995

G

solute carrier family 7 member 11

increases expression

didecyldimethylammonium results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

spermine oxidase

increases expression

didecyldimethylammonium results in increased expression of SMOX mRNA

NCBI chr 3:118,731,814...118,767,242
Ensembl chr 3:118,731,900...118,765,710

G

sequestosome 1

increases expression

didecyldimethylammonium results in increased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5

decreases expression

didecyldimethylammonium results in decreased expression of ST6GALNAC5 mRNA

NCBI chr 2:241,741,933...241,911,214
Ensembl chr 2:241,742,688...241,911,208

G

stanniocalcin 2

increases expression

didecyldimethylammonium results in increased expression of STC2 mRNA

NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973

G

transgelin

decreases expression

didecyldimethylammonium results in decreased expression of TAGLN mRNA

NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668

G

transforming growth factor, beta 1

increases expression
multiple interactions

didecyldimethylammonium results in increased expression of TGFB1 mRNA
SD-208 inhibits the reaction [didecyldimethylammonium results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 2

decreases expression

didecyldimethylammonium results in decreased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

transforming growth factor, beta 3

decreases expression

didecyldimethylammonium results in decreased expression of TGFB3 mRNA

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

thrombospondin 2

decreases expression

didecyldimethylammonium results in decreased expression of THBS2 mRNA

NCBI chr 1:55,670,394...55,699,789
Ensembl chr 1:55,670,394...55,699,789

G

transmembrane protein 14A

decreases expression

didecyldimethylammonium results in decreased expression of TMEM14A mRNA

NCBI chr 9:23,640,594...23,652,379
Ensembl chr 9:23,733,039...23,734,463
Ensembl chr 9:23,733,039...23,734,463

G

transmembrane protein 156

increases expression

didecyldimethylammonium results in increased expression of TMEM156 mRNA

NCBI chr14:43,221,464...43,252,453
Ensembl chr14:43,223,381...43,252,449

G

transmembrane protein 255A

decreases expression

didecyldimethylammonium results in decreased expression of TMEM255A mRNA

NCBI chr X:116,970,793...117,035,008
Ensembl chr X:116,970,695...117,035,008

G

tumor necrosis factor

multiple interactions

didecyldimethylammonium results in increased expression of and results in increased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

increases expression

didecyldimethylammonium results in increased expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

tumor protein p53

increases expression

didecyldimethylammonium results in increased expression of TP53 protein modified form

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tribbles pseudokinase 3

increases expression

didecyldimethylammonium results in increased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

thymic stromal lymphopoietin

increases expression

didecyldimethylammonium results in increased expression of TSLP protein

NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548

G

vimentin

multiple interactions
increases expression

SD-208 inhibits the reaction [didecyldimethylammonium results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

YAE1 maturation factor of ABCE1

increases expression

didecyldimethylammonium results in increased expression of YAE1D1 mRNA

NCBI chr17:47,027,033...47,033,549
Ensembl chr17:47,027,019...47,033,546

ecothiopate iodide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

Echothiophate Iodide results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

albumin

affects binding

Echothiophate Iodide binds to ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

butyrylcholinesterase

decreases activity
multiple interactions

Echothiophate Iodide results in decreased activity of BCHE protein
Echothiophate Iodide inhibits the reaction [BCHE protein results in increased hydrolysis of Butyrylthiocholine]

PMID:7377577 PMID:16213467 PMID:17698511 PMID:21802514

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

neutral cholesterol ester hydrolase 1

decreases activity

Echothiophate Iodide results in decreased activity of NCEH1 protein

NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588

ergothioneine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Ergothioneine inhibits the reaction [Cisplatin results in decreased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

AKT serine/threonine kinase 1

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

caspase 3

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glutamic--pyruvic transaminase

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 6

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein]

NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

solute carrier family 22 member 4

multiple interactions

Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of and results in increased localization of Doxorubicin]
Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of Doxorubicin]

NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720

G

tumor necrosis factor

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

glycine betaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ABI family member 3 binding protein

increases expression

Betaine results in increased expression of ABI3BP mRNA

NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929

G

acetyl-CoA carboxylase alpha

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

actin alpha 2, smooth muscle

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adhesion G protein-coupled receptor G2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA

NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609

G

adenylosuccinate synthase 2

decreases expression

Betaine results in decreased expression of ADSS2 mRNA

NCBI chr13:89,769,240...89,799,577
Ensembl chr13:89,769,244...89,799,604

G

adenosylhomocysteinase

decreases expression

Betaine results in decreased expression of AHCY mRNA

PMID:22945834 PMID:26391144

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

A-kinase interacting protein 1

increases expression

Betaine results in increased expression of AKIP1 mRNA

NCBI chr 1:163,734,730...163,743,648
Ensembl chr 1:163,734,798...163,743,648

G

aldo-keto reductase family 1 member B1

decreases expression

Betaine results in decreased expression of AKR1B1 mRNA

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1, member B7

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA

NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502

G

albumin

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in decreased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 2 family member

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

apurinic/apyrimidinic endodeoxyribonuclease 1

decreases expression

Betaine results in decreased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

amyloid beta precursor protein

multiple interactions

Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

ATPase copper transporting beta

multiple interactions

ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA]

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

axin 1

multiple interactions

[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene

NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615

G

BCL2 associated X, apoptosis regulator

decreases expression

Betaine results in decreased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

affects binding
increases expression

Betaine analog binds to BCL2 protein
Betaine results in increased expression of BCL2 protein

PMID:25080425 PMID:25765238

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

basic helix-loop-helix family, member e40

increases expression

Betaine results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

betaine-homocysteine S-methyltransferase

increases metabolic processing

BHMT protein results in increased metabolism of Betaine

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

BRF1, RNA polymerase III transcription initiation factor subunit

multiple interactions

Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein]

NCBI chr 6:132,034,378...132,081,313
Ensembl chr 6:132,037,272...132,081,278

G

calcium binding protein 39-like

decreases expression

Betaine results in decreased expression of CAB39L mRNA

NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545

G

caspase 1

increases expression

Betaine results in increased expression of CASP1 mRNA

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions

Betaine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein; Betaine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]
Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein]; Betaine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]

PMID:12893363 PMID:20118189 PMID:24632105 PMID:36087182 PMID:37840533

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 113

increases expression

Betaine results in increased expression of CCDC113 mRNA

NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923

G

C-C motif chemokine ligand 2

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

increases expression

Betaine results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 9

increases expression

Betaine results in increased expression of CCL6 mRNA

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

cyclin B2

decreases expression

Betaine results in decreased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

CD44 molecule

decreases expression

Betaine results in decreased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

CDC42 effector protein 2

decreases expression

Betaine results in decreased expression of CDC42EP2 mRNA

NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897

G

cadherin 13

decreases expression

Betaine results in decreased expression of CDH13 mRNA

NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459

G

cyclin-dependent kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase inhibitor 2A

multiple interactions

Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA]

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

carboxylesterase 2C

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

carboxylesterase 3a

increases expression

Betaine results in increased expression of CES3 mRNA

NCBI chr19:32,992,386...33,000,562

G

creatine kinase B

increases expression

Betaine results in increased expression of CKB mRNA

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

CDC28 protein kinase regulatory subunit 1B

decreases expression

Betaine results in decreased expression of CKS1B mRNA

NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636

G

cardiotrophin-like cytokine factor 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA

NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605

G

coactosin-like F-actin binding protein 1

decreases expression

Betaine results in decreased expression of COTL1 mRNA

NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689

G

carnitine palmitoyltransferase 1A

multiple interactions
decreases expression

Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA]
Betaine results in decreased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

C-X-C motif chemokine ligand 16

decreases expression

Betaine results in decreased expression of CXCL16 mRNA

NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA

NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 24

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]
Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1]

PMID:20118189 PMID:21352821

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cysteinyl leukotriene receptor 1

increases expression

Betaine results in increased expression of CYSLTR1 mRNA

NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121

G

death associated protein kinase 1

decreases expression

Betaine results in decreased expression of DAPK1 mRNA

NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991

G

DEPP autophagy regulator 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA

NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542

G

distal-less homeobox 2

increases expression

Betaine results in increased expression of DLX2 mRNA

NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597

G

DNA methyltransferase 1

multiple interactions
increases expression

Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA]
Betaine results in increased expression of DNMT1 mRNA

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA methyltransferase 3 beta

decreases expression

Betaine results in decreased expression of DNMT3B mRNA

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

E2F transcription factor 8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

epithelial cell transforming 2

decreases expression

Betaine results in decreased expression of ECT2 mRNA

NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911

G

eukaryotic elongation factor-2 kinase

increases expression

Betaine results in increased expression of EEF2K mRNA

NCBI chr 1:175,393,119...175,456,756
Ensembl chr 1:175,393,154...175,455,164

G

epidermal growth factor receptor

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

increases expression
multiple interactions

Betaine results in increased expression of EGR1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA

PMID:26391144 PMID:33549593

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

E74 like ETS transcription factor 3

decreases expression

Betaine results in decreased expression of ELF3 mRNA

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

ER membrane protein complex subunit 9

increases expression

Betaine results in increased expression of EMC9 mRNA

NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098

G

Eph receptor B6

increases expression

Betaine results in increased expression of EPHB6 mRNA

NCBI chr 4:70,491,973...70,507,230
Ensembl chr 4:70,491,973...70,507,230

G

establishment of sister chromatid cohesion N-acetyltransferase 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA

NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306

G

coagulation factor VIII

multiple interactions
increases secretion

Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form
Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form

NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857

G

coagulation factor IX

increases secretion

Betaine results in increased secretion of F9 protein

NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835

G

fatty acid binding protein 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

fatty acid synthase

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibronectin leucine rich transmembrane protein 3

increases expression

Betaine results in increased expression of FLRT3 mRNA

NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841

G

FXYD domain-containing ion transport regulator 2

decreases expression

Betaine results in decreased expression of FXYD2 mRNA; Betaine results in decreased expression of FXYD2 mRNA alternative form

NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

galanin and GMAP prepropeptide

multiple interactions

Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein]

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

glucokinase

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

G protein subunit alpha 14

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA

NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423

G

glycerophosphocholine phosphodiesterase 1

increases expression
multiple interactions

Betaine results in increased expression of GPCPD1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA

PMID:26391144 PMID:33549593

NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517

G

glutamic--pyruvic transaminase

multiple interactions

Betaine inhibits the reaction [sodium arsenite results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione S-transferase alpha 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase, mu 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glucuronidase, beta

multiple interactions

Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein]

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

H2A.Z variant histone 1

decreases expression

Betaine results in decreased expression of H2AZ1 mRNA

NCBI chr 2:226,355,668...226,357,984
Ensembl chr 2:226,355,708...226,358,485

G

huntingtin interacting protein 1

decreases expression

Betaine results in decreased expression of HIP1 mRNA

NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725

G

high mobility group box 2

decreases expression

Betaine results in decreased expression of HMGB2 mRNA

NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140

G

heme oxygenase 1

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

decreases expression

Betaine results in decreased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

inhibitor of DNA binding 2

increases expression

Betaine results in increased expression of ID2 mRNA

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of Betaine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 6

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin receptor substrate 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

iroquois homeobox 4

decreases expression

Betaine results in decreased expression of IRX4 mRNA

NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549

G

integrin subunit alpha 8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA

NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510

G

integrin subunit beta 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA

NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Betaine results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KH RNA binding domain containing, signal transduction associated 3

decreases expression

Betaine results in decreased expression of KHDRBS3 mRNA

NCBI chr 7:100,837,707...100,995,644
Ensembl chr 7:100,837,934...100,988,460

G

kinesin family member 1B

increases expression

Betaine results in increased expression of KIF1B mRNA

NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778

G

kinesin family member 22

decreases expression

Betaine results in decreased expression of KIF22 mRNA

NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401

G

KLF transcription factor 10

increases expression

Betaine results in increased expression of KLF10 mRNA

NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994

G

keratin 2

increases expression

Betaine results in increased expression of KRT2 mRNA; Betaine results in increased expression of KRT2 protein

NCBI chr 7:132,940,879...132,948,031
Ensembl chr 7:132,940,862...132,947,963

G

keratin 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA

NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019

G

leucyl-tRNA synthetase 1

decreases expression

Betaine results in decreased expression of LARS1 mRNA

NCBI chr18:34,201,555...34,256,003
Ensembl chr18:34,201,549...34,255,931

G

leptin receptor

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

lin-9 DREAM MuvB core complex component

decreases expression

Betaine results in decreased expression of LIN9 mRNA

NCBI chr13:92,374,612...92,419,664
Ensembl chr13:92,374,593...92,419,654

G

LRAT domain containing 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA

NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319

G

leucine rich repeat containing 24

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA

NCBI chr 7:108,437,296...108,444,561
Ensembl chr 7:108,437,296...108,444,438

G

mitogen activated protein kinase kinase kinase kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA

NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493

G

membrane associated ring-CH-type finger 6

multiple interactions
decreases stability

Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein]

NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910

G

minichromosome maintenance complex component 3

decreases expression

Betaine results in decreased expression of MCM3 mRNA

NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314

G

minichromosome maintenance complex component 4

decreases expression

Betaine results in decreased expression of MCM4 mRNA

NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144

G

minichromosome maintenance complex component 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA

NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389

G

minichromosome maintenance complex component 6

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

minichromosome maintenance complex component 7

decreases expression

Betaine results in decreased expression of MCM7 mRNA

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

microtubule associated monooxygenase, calponin and LIM domain containing 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA

NCBI chr20:44,974,137...44,986,089
Ensembl chr20:44,974,138...44,986,089

G

marker of proliferation Ki-67

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

decreases expression

Betaine results in decreased expression of MTHFD1L mRNA

NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases expression

Betaine results in decreased expression of MTHFD2 mRNA

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

Betaine inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYCL proto-oncogene, bHLH transcription factor

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA

NCBI chr 5:135,274,713...135,281,584
Ensembl chr 5:135,274,748...135,281,582

G

NBL1, DAN family BMP antagonist

increases expression

Betaine results in increased expression of NBL1 mRNA

NCBI chr 5:151,318,752...151,329,948
Ensembl chr 5:151,318,754...151,338,719

G

NCK interacting protein with SH3 domain

decreases expression

Betaine results in decreased expression of NCKIPSD mRNA

NCBI chr 8:109,511,484...109,522,622
Ensembl chr 8:109,511,658...109,522,246

G

NDRG family member 4

decreases expression

Betaine results in decreased expression of NDRG4 mRNA

NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914

G

NFE2 like bZIP transcription factor 2

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 12

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA

NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934

G

NLR family, pyrin domain containing 3

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of NLRP3 mRNA]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nuclear protein 1, transcriptional regulator

decreases expression

Betaine results in decreased expression of NUPR1 mRNA

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

8-oxoguanine DNA glycosylase

multiple interactions

Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

Purkinje cell protein 4

increases expression

Betaine results in increased expression of PCP4 mRNA

NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725

G

phosphatidylcholine transfer protein

decreases expression

Betaine results in decreased expression of PCTP mRNA

NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867

G

period circadian regulator 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

DNA polymerase alpha 2, accessory subunit

decreases expression

Betaine results in decreased expression of POLA2 mRNA

NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348

G

DNA polymerase epsilon 2, accessory subunit

decreases expression

Betaine results in decreased expression of POLE2 mRNA

NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein
Betaine results in decreased expression of PPARA mRNA

PMID:20118189 PMID:22945834

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein phosphatase 1, regulatory subunit 3G

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA

NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525

G

protein phosphatase 2 catalytic subunit alpha

multiple interactions

Betaine inhibits the reaction [Ethanol results in decreased methylation of PPP2CA protein]

NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862

G

serine protease 23

increases expression

Betaine results in increased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

serine protease 8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA

NCBI chr 1:182,536,229...182,540,745
Ensembl chr 1:182,536,229...182,540,815

G

presenilin 1

multiple interactions

Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter]

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

prostaglandin-endoperoxide synthase 1

decreases expression

Betaine results in decreased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

RAN binding protein 3-like

decreases expression

Betaine results in decreased expression of RANBP3L mRNA

NCBI chr 2:58,057,887...58,113,158
Ensembl chr 2:58,058,263...58,113,172

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Betaine inhibits the reaction [Fructose results in decreased activity of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

regulatory factor X4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA

NCBI chr 7:18,853,065...19,015,378
Ensembl chr 7:18,853,322...19,014,967

G

regulator of G-protein signaling 16

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA

NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857

G

regulator of G-protein signaling 2

increases expression

Betaine results in increased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

ribonucleotide reductase regulatory subunit M2

decreases expression
multiple interactions

Betaine results in decreased expression of RRM2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA

PMID:26391144 PMID:33549593

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

S100 calcium binding protein A8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

stearoyl-CoA desaturase

decreases expression

Betaine results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

secreted and transmembrane 1B

increases expression

Betaine results in increased expression of SECTM1A mRNA

NCBI chr10:106,324,070...106,333,779
Ensembl chr10:106,325,203...106,333,769

G

serine incorporator 2

decreases expression

Betaine results in decreased expression of SERINC2 mRNA

NCBI chr 5:142,592,308...142,614,628
Ensembl chr 5:142,592,309...142,618,364

G

serine (or cysteine) peptidase inhibitor, clade A, member 3N

decreases expression

Betaine results in decreased expression of SERPINA3N mRNA

NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433

G

solute carrier family 16, member 6

increases expression

Betaine results in increased expression of SLC16A6 mRNA

NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779

G

solute carrier family 22 member 5

multiple interactions

Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 25, member 30

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA

NCBI chr15:51,076,998...51,099,613
Ensembl chr15:51,077,002...51,099,613

G

solute carrier family 36 member 1

increases uptake

SLC36A1 protein results in increased uptake of Betaine

NCBI chr10:39,319,062...39,357,374
Ensembl chr10:39,324,337...39,354,217

G

solute carrier family 6 member 12

multiple interactions

Betaine inhibits the reaction [Lipopolysaccharides results in increased expression of SLC6A12 mRNA]

NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750

G

solute carrier family 6 member 20a

increases uptake

SLC6A20B protein results in increased uptake of Betaine

NCBI chr 8:123,282,325...123,322,609
Ensembl chr 8:123,281,472...123,322,573

G

solute carrier family 6 member 9

decreases expression

Betaine results in decreased expression of SLC6A9 mRNA

NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728

G

sorting nexin 10

decreases expression

Betaine results in decreased expression of SNX10 mRNA

NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996

G

suppressor of cytokine signaling 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

sclerostin domain containing 1

increases expression

Betaine results in increased expression of SOSTDC1 mRNA

NCBI chr 6:53,051,336...53,055,510
Ensembl chr 6:53,051,354...53,055,579

G

SPC25 component of NDC80 kinetochore complex

decreases expression

Betaine results in decreased expression of SPC25 mRNA

NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959

G

signal sequence receptor subunit 4

decreases expression

Betaine results in decreased expression of SSR4 mRNA

NCBI chr X:151,524,191...151,528,218
Ensembl chr X:151,524,009...151,528,202

G

signal transducer and activator of transcription 3

multiple interactions

Betaine promotes the reaction [Isoproterenol results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

stathmin 1

decreases expression

Betaine results in decreased expression of STMN1 mRNA

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

syntaxin binding protein 1

decreases expression

Betaine results in decreased expression of STXBP1 mRNA

NCBI chr 3:16,076,725...16,138,431
Ensembl chr 3:16,076,391...16,138,369

G

sulfotransferase family 1E member 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

TGF-beta activated kinase 1/MAP3K7 binding protein 1

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of TAB1 mRNA]

NCBI chr 7:111,675,829...111,707,058
Ensembl chr 7:111,686,371...111,707,058

G

transforming growth factor, beta 2

increases expression

Betaine results in increased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

toll-like receptor 4

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA]; Betaine inhibits the reaction [sodium arsenite results in increased expression of TNF protein]
Betaine inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]

PMID:22945834 PMID:36087182 PMID:37840533

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tribbles pseudokinase 2

decreases expression

Betaine results in decreased expression of TRIB2 mRNA

NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370

G

unc-51 like autophagy activating kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA

NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966

G

uroplakin 3B like 1

decreases expression

Betaine results in decreased expression of UPK3BL1 mRNA

NCBI chr12:20,610,353...20,616,366
Ensembl chr12:20,610,353...20,616,366

G

ubiquitin specific peptidase 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA

NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331

G

vanin 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA

NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395

G

WNK lysine deficient protein kinase 4

decreases expression

Betaine results in decreased expression of WNK4 mRNA

NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,188,812...86,231,829

G

Y box binding protein 2

decreases expression

Betaine results in decreased expression of YBX2 mRNA

NCBI chr10:54,659,719...54,665,371
Ensembl chr10:54,659,719...54,665,371

Hexamethonium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arginine vasopressin

multiple interactions

Hexamethonium promotes the reaction [Dexamethasone results in increased activity of AVP protein]

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

bradykinin receptor B2

affects response to substance

BDKRB2 affects the susceptibility to Hexamethonium

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

baculoviral IAP repeat-containing 5

multiple interactions

Hexamethonium affects the reaction [Nicotine results in increased expression of BIRC5 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

cyclin-dependent kinase 4

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

Hexamethonium results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]

PMID:7756618 PMID:14645658

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]

PMID:7756618 PMID:14645658

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

Hexamethonium results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Hexamethonium inhibits the reaction [Hydrochloric Acid results in increased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

mitogen activated protein kinase 1

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]

PMID:18448488 PMID:20106947

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]

PMID:18448488 PMID:20106947

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

marker of proliferation Ki-67

multiple interactions

Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein]

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

neuropeptide Y

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in increased expression of NPY mRNA]

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

signal transducer and activator of transcription 3

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]
Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form]

PMID:18448488 PMID:20106947 PMID:29501575

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

X-linked inhibitor of apoptosis

multiple interactions

Hexamethonium affects the reaction [Nicotine results in increased expression of XIAP protein]

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

L-proline betaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205

G

interleukin 1 beta

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

matrix metallopeptidase 13

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 3

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

NFKB inhibitor alpha

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prostaglandin-endoperoxide synthase 2

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

meldonium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA dehydrogenase, long chain

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of ACADL mRNA

NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220

G

acyl-CoA dehydrogenase medium chain

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of ACADM mRNA

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

acyl-CoA dehydrogenase, very long chain

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACADVL mRNA

NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075

G

acyl-CoA oxidase 1

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

carnitine palmitoyltransferase 1B

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1B mRNA

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

carnitine palmitoyltransferase 1c

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1C mRNA

NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342

G

hexokinase 1

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of HK1 mRNA

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

pyruvate dehydrogenase kinase 1

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of PDK1 mRNA

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

peroxisome proliferator activated receptor alpha

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

PPARG coactivator 1 alpha

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of PPARGC1A mRNA

PMID:27559315 PMID:32389661

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PPARG coactivator 1 beta

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARGC1B mRNA

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194

G

solute carrier family 22 member 5

increases uptake

SLC22A5 protein results in increased uptake of 3-(2,2,2-trimethylhydrazine)propionate

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 2 member 4

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of SLC2A4 mRNA

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 5 member 2

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of SLC5A2 mRNA

NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306

G

transcription factor A, mitochondrial

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of TFAM mRNA

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

methacholine chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions
increases response to substance

Cyclosporine inhibits the reaction [[AHR protein results in increased susceptibility to Antigens] which results in increased susceptibility to Methacholine Chloride]
[AHR protein results in increased susceptibility to Antigens] which results in increased susceptibility to Methacholine Chloride; AHR protein results in increased susceptibility to Methacholine Chloride

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

bone morphogenetic protein receptor type 2

multiple interactions

BMPR2 protein affects the susceptibility to [Methacholine Chloride co-treated with Antigens, Dermatophagoides]

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

complement C3

multiple interactions

C3 protein affects the susceptibility to [Ozone co-treated with Methacholine Chloride]

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

calcium voltage-gated channel subunit alpha1 E

multiple interactions

1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Atropine inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Calcium inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Heparin affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]; Ro 31-8425 inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]

NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450

G

CF transmembrane conductance regulator

multiple interactions

3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Methacholine Chloride promotes the reaction [CFTR protein results in increased export of Chlorides]]; Methacholine Chloride promotes the reaction [CFTR protein results in increased export of Chlorides]

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

carboxypeptidase E

increases response to substance

CPE gene mutant form results in increased susceptibility to Methacholine Chloride

NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233

G

C-X-C motif chemokine receptor 2

multiple interactions

Ozone promotes the reaction [CXCR2 protein affects the susceptibility to Methacholine Chloride]

NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425

G

Fc epsilon receptor II

increases expression

Methacholine Chloride results in increased expression of FCER2 protein

NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476

G

G protein-coupled receptor kinase 3

affects response to substance

GRK3 mutant form affects the susceptibility to Methacholine Chloride

NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262

G

interleukin 1 receptor antagonist

multiple interactions
increases expression

IL1RN protein results in decreased susceptibility to [Ozone co-treated with Methacholine Chloride]
Methacholine Chloride results in increased expression of IL1RN protein

PMID:14754758 PMID:15801332

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

leptin

increases response to substance

LEP gene mutant form results in increased susceptibility to Methacholine Chloride

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

nitric oxide synthase 2

multiple interactions

NOS2 protein affects the reaction [2-chloroethyl ethyl sulfide affects the susceptibility to Methacholine Chloride]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
decreases response to substance

N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [NOS3 gene mutant form results in decreased susceptibility to Methacholine Chloride]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

NR1I2 protein affects the susceptibility to [5-alpha-Dihydroprogesterone co-treated with Methacholine Chloride]

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

tumor necrosis factor

multiple interactions

[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride; Chlorpromazine inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]; Cromolyn Sodium inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 1A

increases response to substance

TNFRSF1A protein results in increased susceptibility to Methacholine Chloride

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

transient receptor potential cation channel, subfamily C, member 3

increases activity

Methacholine Chloride results in increased activity of TRPC3 protein

NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855

methyltrioctylammonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

iodothyronine deiodinase 1

decreases activity

trioctylmethylammonium results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

decreases activity

trioctylmethylammonium results in decreased activity of DIO2 protein

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

decreases activity

trioctylmethylammonium results in decreased activity of DIO3 protein

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

iodotyrosine deiodinase

multiple interactions

trioctylmethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

N-methylnicotinate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

angiotensinogen

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

autophagy related 7

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

BCL2 associated X, apoptosis regulator

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]
[trigonelline co-treated with Cisplatin] results in increased expression of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein

PMID:31935362 PMID:33148531

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]
[trigonelline co-treated with Cisplatin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein

PMID:31935362 PMID:33148531

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

beclin 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in decreased expression of BECN1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

caspase 3

increases activity
multiple interactions

trigonelline results in increased activity of CASP3 protein
[trigonelline co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]

PMID:26593444 PMID:31935362 PMID:33148531

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

CD36 molecule

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of CD36 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of CD36 protein]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

DNA-damage inducible transcript 3

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

epidermal growth factor

multiple interactions

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
trigonelline results in decreased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

ferritin heavy chain 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of FTH1 mRNA

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of FTL mRNA

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

hexosaminidase subunit beta

multiple interactions

trigonelline inhibits the reaction [iodixanol results in increased secretion of HEXB protein]

NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223

G

heme oxygenase 1

decreases expression

trigonelline results in decreased expression of HMOX1 mRNA; trigonelline results in decreased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 1 beta

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]; trigonelline inhibits the reaction [INS2 protein affects the abundance of angiotensin I (1-7)]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

Kelch-like ECH-associated protein 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in decreased expression of KEAP1 mRNA

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

leptin receptor

affects abundance

LEPR affects the abundance of trigonelline

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]
trigonelline results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
trigonelline results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

mechanistic target of rapamycin kinase

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

trigonelline results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]; trigonelline inhibits the reaction [ferric citrate affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Cisplatin]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]]; trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]
trigonelline results in decreased phosphorylation of NFE2L2 protein

PMID:24015256 PMID:29211853 PMID:29959986 PMID:33148531

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
decreases expression

trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA]
trigonelline results in decreased expression of NQO1 mRNA; trigonelline results in decreased expression of NQO1 protein

PMID:24015256 PMID:29959986 PMID:33148531

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

poly (ADP-ribose) polymerase 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased cleavage of PARP1 protein]
[trigonelline co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein

PMID:30208301 PMID:33148531

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phospholipase C, gamma 1

multiple interactions

trigonelline inhibits the reaction [iodixanol results in increased phosphorylation of PLCG1 protein]

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

perilipin 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PLIN1 protein]

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of PPARG protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

sequestosome 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SQSTM1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

tumor necrosis factor

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

O-acetyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

apurinic/apyrimidinic endodeoxyribonuclease 1

increases expression

Acetylcarnitine results in increased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

ATPase H+ transporting V1 subunit F

increases expression

Acetylcarnitine results in increased expression of ATP6V1F mRNA

NCBI chr 4:58,067,666...58,070,628

G

complement C1q A chain

decreases expression

Acetylcarnitine results in decreased expression of C1QA mRNA

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534

G

complement C4B

decreases expression

Acetylcarnitine results in decreased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

caspase 3

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of CASP3 mRNA]

PMID:20067779 PMID:29278859

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of CAT mRNA]

PMID:20067779 PMID:26349760 PMID:29278859

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Acetylcarnitine

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

citrate synthase

decreases activity

Acetylcarnitine results in decreased activity of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

cathepsin S

decreases expression

Acetylcarnitine results in decreased expression of CTSS mRNA

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

C-X-C motif chemokine ligand 14

decreases expression

Acetylcarnitine results in decreased expression of CXCL14 mRNA

NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839

G

early growth response 1

multiple interactions

Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of EGR1 mRNA]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

glial fibrillary acidic protein

decreases expression

Acetylcarnitine results in decreased expression of GFAP mRNA

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutathione-disulfide reductase

multiple interactions

Acetylcarnitine inhibits the reaction [Acetaminophen results in decreased expression of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase pi 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in decreased expression of GSTP1 mRNA]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

heme oxygenase 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heme oxygenase 2

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX2 mRNA]

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

heat shock protein family B (small) member 1

decreases expression

Acetylcarnitine results in decreased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of Acetylcarnitine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Acetylcarnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 1 beta

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

microsomal glutathione S-transferase 1

increases expression

Acetylcarnitine results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

mitochondrially encoded cytochrome c oxidase I

multiple interactions

Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of COX1 mRNA]

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

nerve growth factor

multiple interactions

Acetylcarnitine inhibits the reaction [Cisplatin results in decreased expression of NGF protein]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS1 mRNA]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

phenylalanine hydroxylase

decreases expression

Acetylcarnitine results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

PTEN induced kinase 1

multiple interactions

Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PINK1]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Acetylcarnitine results in increased expression of PPARGC1A protein
[Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PRKN]

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

proteasome 20S subunit beta 6

increases expression

Acetylcarnitine results in increased expression of PSMB6 mRNA

NCBI chr10:55,239,256...55,241,586
Ensembl chr10:55,239,241...55,241,586

G

prothymosin alpha

increases expression

Acetylcarnitine results in increased expression of PTMA mRNA

NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S17

increases expression

Acetylcarnitine results in increased expression of RPS17 mRNA

NCBI chr 1:135,295,920...135,298,506
Ensembl chr 1:135,295,919...135,298,535
Ensembl chr 8:135,295,919...135,298,535

G

src kinase associated phosphoprotein 2

decreases expression

Acetylcarnitine results in decreased expression of SKAP2 mRNA

NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891

G

solute carrier family 25 member 20

multiple interactions

Acetylcarnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

synuclein alpha

multiple interactions

[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Acetylcarnitine inhibits the reaction [Rotenone results in increased expression of SNCA protein]

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

troponin I3, cardiac type

multiple interactions

Acetylcarnitine inhibits the reaction [Cisplatin results in increased expression of TNNI3 protein]

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

O-butanoyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of butyrylcarnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

O-octanoylcarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carnitine O-octanoyltransferase

increases chemical synthesis

CROT protein results in increased chemical synthesis of octanoylcarnitine

NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109

O-palmitoylcarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Palmitoylcarnitine

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

glutaminase

increases chemical synthesis

GLS protein results in increased chemical synthesis of Palmitoylcarnitine

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

protein phosphatase 3, regulatory subunit B, alpha

decreases metabolic processing

PPP3R1 gene mutant form results in decreased metabolism of Palmitoylcarnitine

NCBI chr14:91,556,743...91,606,391
Ensembl chr14:91,604,121...91,606,907

G

protein kinase AMP-activated catalytic subunit alpha 1

increases chemical synthesis

PRKAA1 protein results in increased chemical synthesis of Palmitoylcarnitine

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

perifosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

[perifosine co-treated with Butyrates] results in increased secretion of AIFM1 protein; [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [perifosine co-treated with vorinostat] results in increased secretion of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

[perifosine co-treated with Butyrates] results in decreased activity of AKT1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; [perifosine co-treated with Vorinostat] results in decreased activity of AKT1 protein; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Butyrates]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Vorinostat]; perifosine inhibits the reaction [cyadox results in increased phosphorylation of AKT1 protein]
perifosine results in decreased phosphorylation of AKT1 protein
[perifosine co-treated with temsirolimus] results in decreased activity of AKT1 protein

PMID:15781658 PMID:21267448 PMID:30265530 PMID:31445927

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2-antagonist/killer 1

multiple interactions

[perifosine co-treated with Butyrates] results in decreased expression of BAK1 protein; [perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein; [perifosine co-treated with vorinostat] results in decreased expression of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

multiple interactions

[perifosine co-treated with Butyrates] results in increased activity of BAX protein; [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; [perifosine co-treated with vorinostat] results in increased activity of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

multiple interactions
decreases expression

[perifosine co-treated with Butyrates] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP3 protein
perifosine results in decreased expression of CASP3 protein

PMID:15781658 PMID:25416439

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases expression

[perifosine co-treated with Butyrates] results in increased activity of CASP8 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [perifosine co-treated with Vorinostat] results in increased activity of CASP8 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]

PMID:15781658 PMID:32587277

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

perifosine inhibits the reaction [Mitomycin results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cytochrome c, somatic

multiple interactions

[perifosine co-treated with Butyrates] affects the localization of CYCS protein; [perifosine co-treated with trichostatin A] affects the localization of CYCS protein; [perifosine co-treated with vorinostat] affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

epidermal growth factor

multiple interactions

perifosine inhibits the reaction [cyadox results in increased expression of EGF]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of EGF]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

Fas cell surface death receptor

affects response to substance

perifosine affects the susceptibility to FAS protein

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

forkhead box O1

multiple interactions

[perifosine co-treated with cyadox] results in increased expression of FOXO1 mRNA; [perifosine co-treated with Hydrogen Peroxide] results in increased expression of FOXO1 mRNA
perifosine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein]

PMID:30265530 PMID:33078829

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

galactosidase, beta 1

multiple interactions

perifosine inhibits the reaction [Mitomycin results in increased activity of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

linker for activation of T cells family, member 2

multiple interactions
decreases response to substance
decreases expression

ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]
LAT2 protein results in decreased susceptibility to perifosine

PMID:23001822 PMID:32587277

NCBI chr12:22,104,173...22,118,294
Ensembl chr12:22,104,219...22,118,288

G

mitogen activated protein kinase kinase 1

multiple interactions

MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase 1

multiple interactions

[perifosine co-treated with Butyrates] results in decreased activity of MAPK1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[perifosine co-treated with Butyrates] results in decreased activity of MAPK3 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[perifosine co-treated with Butyrates] results in increased activity of MAPK8 protein; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; [perifosine co-treated with vorinostat] results in increased activity of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mechanistic target of rapamycin kinase

multiple interactions

[perifosine co-treated with temsirolimus] results in decreased activity of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

tumor necrosis factor

increases response to substance

perifosine results in increased susceptibility to TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA]; perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

phosphatidylcholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases secretion

ABCB11 protein results in increased secretion of Phosphatidylcholines

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

affects export
affects transport

ABCB1 protein affects the export of Phosphatidylcholines
ABCB1 protein affects the transport of Phosphatidylcholines

PMID:11147995 PMID:11745043

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

affects transport
affects export

ABCB4 protein affects the transport of Phosphatidylcholines
ABCB4 protein affects the export of Phosphatidylcholines

PMID:11745043 PMID:15696852

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

acetyl-CoA acetyltransferase 1

decreases activity

Phosphatidylcholines results in decreased activity of ACAT1 protein

NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855

G

adiponectin, C1Q and collagen domain containing

decreases expression

Phosphatidylcholines results in decreased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

aryl hydrocarbon receptor

multiple interactions
increases abundance

PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

amyloid beta precursor protein

multiple interactions

[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arsenite methyltransferase

affects metabolic processing

AS3MT gene mutant form affects the metabolism of Phosphatidylcholines

NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872

G

BCL2 associated X, apoptosis regulator

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

basic helix-loop-helix ARNT like 1

increases abundance

BMAL1 gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

caspase 3

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

increases expression

Phosphatidylcholines results in increased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

multiple interactions

Phosphatidylcholines promotes the reaction [rubitecan results in decreased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin dependent kinase 2

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

carboxylesterase 1D

decreases expression

Phosphatidylcholines results in decreased expression of CES1D mRNA

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

collagen type I alpha 1 chain

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

C-reactive protein

affects binding
decreases activity

CRP protein binds to Phosphatidylcholines
Phosphatidylcholines results in decreased activity of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects activity

Phosphatidylcholines affects the activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450 family 7 subfamily A member 1

increases activity

Phosphatidylcholines results in increased activity of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

ectonucleotide pyrophosphatase/phosphodiesterase 7

increases hydrolysis

ENPP7 protein results in increased hydrolysis of Phosphatidylcholines

NCBI chr10:104,242,169...104,247,185
Ensembl chr10:104,242,223...104,246,589

G

fatty acid synthase

multiple interactions

[orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 19

decreases abundance

FGF19 protein results in decreased abundance of Phosphatidylcholines

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

glutathione peroxidase 4

multiple interactions

GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases activity

Phosphatidylcholines results in increased activity of HMGCR protein

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

insulin-like growth factor 1

increases degradation

IGF1 protein results in increased degradation of Phosphatidylcholines

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 10

increases expression

Phosphatidylcholines results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

increases expression
multiple interactions

Phosphatidylcholines results in increased expression of IL1B mRNA
Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein

PMID:23911798 PMID:30958839

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases expression

Phosphatidylcholines results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

leptin

decreases expression

Phosphatidylcholines results in decreased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase C, hepatic type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines
LIPC gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lipase E, hormone sensitive type

increases expression

Phosphatidylcholines results in increased expression of LIPE mRNA

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

lipase G, endothelial type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines
LIPG gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

G

lactotransferrin

multiple interactions

[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795

G

matrix metallopeptidase 2

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

NADPH oxidase 4

multiple interactions

NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

nuclear receptor subfamily 0, group B, member 2

decreases abundance

NR0B2 protein results in decreased abundance of Phosphatidylcholines

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Phosphatidylcholines

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

platelet-activating factor acetylhydrolase 1b, regulatory subunit 1

multiple interactions
increases secretion

PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines]
PAFAH1B1 protein results in increased secretion of Phosphatidylcholines

NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808

G

platelet-activating factor acetylhydrolase 2

multiple interactions

PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 5:146,607,050...146,636,203
Ensembl chr 5:146,613,498...146,634,943

G

phosphate cytidylyltransferase 1A, choline

multiple interactions

PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]

NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357

G

phosphatidylethanolamine N-methyltransferase

multiple interactions

PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]

NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013

G

perilipin 1

increases expression

Phosphatidylcholines results in increased expression of PLIN1 mRNA

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

phospholipid phosphatase 6

multiple interactions
increases chemical synthesis

PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]

NCBI chr 1:226,679,100...226,681,952
Ensembl chr 1:226,679,100...226,681,949

G

patatin-like phospholipase domain containing 2

decreases expression

Phosphatidylcholines results in decreased expression of PNPLA2 mRNA

NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805

G

patatin-like phospholipase domain containing 6

affects abundance

PNPLA6 protein affects the abundance of Phosphatidylcholines

NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734

G

paraoxonase 2

increases activity
increases expression

Phosphatidylcholines results in increased activity of PON2 protein
Phosphatidylcholines results in increased expression of PON2 mRNA

NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248

G

paraoxonase 3

multiple interactions

Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]

NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855

G

peroxisome proliferator-activated receptor gamma

increases expression

Phosphatidylcholines results in increased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 beta

increases abundance

PPARGC1B results in increased abundance of Phosphatidylcholines

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194

G

phosphatase and tensin homolog

affects binding
multiple interactions

PTEN protein binds to Phosphatidylcholines
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

resistin

decreases expression

Phosphatidylcholines results in decreased expression of RETN mRNA

NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620

G

surfactant protein A1

multiple interactions

[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]

NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685

G

transforming growth factor, beta 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions
increases expression
increases abundance

GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
Phosphatidylcholines results in increased expression of TNF mRNA
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein

PMID:16141546 PMID:22433871 PMID:23911798 PMID:30958839

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thioredoxin 1

multiple interactions

[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

pyocyanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

increases expression
multiple interactions

Pyocyanine results in increased expression of AHR mRNA
Pyocyanine promotes the reaction [AHR protein binds to TARDBP promoter]

PMID:28476168 PMID:31078726

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

activating transcription factor 6

increases activity

Pyocyanine results in increased activity of ATF6 protein

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

C-C motif chemokine ligand 5

decreases expression

Pyocyanine results in decreased expression of CCL5 mRNA; Pyocyanine results in decreased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

catenin beta 1

increases expression

Pyocyanine results in increased expression of CTNNB1 mRNA

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

Pyocyanine results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

epidermal growth factor receptor

increases phosphorylation

Pyocyanine results in increased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

fatty acid binding protein 4

decreases expression

Pyocyanine results in decreased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

Pyocyanine results in increased expression of GCLC mRNA
[Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

heat shock transcription factor 1

increases activity

Pyocyanine results in increased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

interleukin 10

increases expression

Pyocyanine results in increased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

decreases expression

Pyocyanine results in decreased expression of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 6

increases expression

Pyocyanine results in increased expression of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

mitogen activated protein kinase kinase 1

increases phosphorylation

Pyocyanine results in increased phosphorylation of MAP2K1 protein

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

increases phosphorylation

Pyocyanine results in increased phosphorylation of MAP2K2 protein

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]

PMID:24015256 PMID:24316274

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

Pyocyanine results in increased phosphorylation of MAPK3 protein
Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]

PMID:24015256 PMID:24316274

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases activity

1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with RTKI cpd] inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein; RTKI cpd inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein]
Pyocyanine results in increased activity of NFE2L2 protein

PMID:24015256 PMID:27613716

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

Pyocyanine results in increased expression of NQO1 mRNA
[Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

peroxisome proliferator-activated receptor gamma

decreases expression

Pyocyanine results in decreased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

TAR DNA binding protein

multiple interactions

Pyocyanine promotes the reaction [AHR protein binds to TARDBP promoter]

NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055

G

tumor necrosis factor

increases expression

Pyocyanine results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

serpentine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity
multiple interactions

serpentine (alkaloid) results in decreased activity of CYP2D6 protein
serpentine (alkaloid) inhibits the reaction [CYP2D6 protein affects the metabolism of Dextromethorphan]

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

tiotropium bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor, muscarinic 1

affects binding

Tiotropium Bromide binds to CHRM1 protein

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

cholinergic receptor, muscarinic 2

affects binding

Tiotropium Bromide binds to CHRM2 protein

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

cholinergic receptor, muscarinic 3

affects binding

Tiotropium Bromide binds to CHRM3 protein

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

G

cholinergic receptor, muscarinic 4

affects binding

Tiotropium Bromide binds to CHRM4 protein

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

cholinergic receptor, muscarinic 5

affects binding

Tiotropium Bromide binds to CHRM5 protein

NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252

G

endothelin 1

multiple interactions

Tiotropium Bromide inhibits the reaction [Oxotremorine results in increased expression of EDN1 mRNA]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

paraoxonase 1

decreases activity

Tiotropium Bromide results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

tumor necrosis factor

decreases secretion

Tiotropium Bromide results in decreased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

tiquizium bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

thiaton results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

myeloperoxidase

multiple interactions

thiaton inhibits the reaction [Indomethacin results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nitric oxide synthase 2

multiple interactions

thiaton inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

trospium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases transport

valspodar inhibits the reaction [ABCB1 protein results in increased transport of trospium chloride]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

solute carrier family 22 member 1

decreases activity
increases metabolic processing

trospium chloride results in decreased activity of SLC22A1 protein
SLC22A1 protein results in increased metabolism of trospium chloride

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 2

decreases activity

trospium chloride results in decreased activity of SLC22A2 protein

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier organic anion transporter family, member 1a4

increases metabolic processing
decreases activity

SLCO1A2 protein results in increased metabolism of trospium chloride
trospium chloride results in decreased activity of SLCO1A2 protein; trospium chloride results in decreased activity of SLCO1A2 protein alternative form

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

decreases activity

trospium chloride results in decreased activity of SLCO1B3 protein

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

vecuronium bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily G member 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein]

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

cholinergic receptor, muscarinic 1

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM1 protein]

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

cholinergic receptor, muscarinic 2

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM2 protein]

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

cholinergic receptor, muscarinic 3

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein]

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

G

cholinergic receptor, muscarinic 4

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM4 protein]

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

cholinergic receptor, muscarinic 5

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM5 protein]

NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

PMID:14645658 PMID:16931985

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

PMID:14645658 PMID:16931985

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 protein]

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 protein]

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

early growth response 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 protein]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

ETS transcription factor ELK1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of ELK1 protein]

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

histone deacetylase 4

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 protein]

NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164

G

hexosaminidase subunit beta

increases secretion

Vecuronium Bromide results in increased secretion of HEXB protein

NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223

G

hydroxysteroid 11-beta dehydrogenase 2

increases expression
multiple interactions

Vecuronium Bromide results in increased expression of HSD11B2 mRNA; Vecuronium Bromide results in increased expression of HSD11B2 protein
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 protein]

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

mitogen activated protein kinase 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nuclear receptor subfamily 1, group H, member 2

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 protein]

NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 protein]

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

scavenger receptor class B, member 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein]

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

steroidogenic acute regulatory protein

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR protein]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19844
chemical entity	19842
molecular entity	19842
ion	16715
organic ion	9898
organic cation	8956
quaternary ammonium ion	5287
quaternary nitrogen compound	876
LSM-5686	0
ammonium betaine +	367
iminium betaine +	56
nitrilium betaine +	0
quaternary ammonium salt +	551
Path 2
Term	Annotations
CHEBI ontology	19844
subatomic particle	19842
composite particle	19842
hadron	19842
baryon	19842
nucleon	19809
atomic nucleus	19842
atom	19842
main group element atom	19792
main group molecular entity	19792
s-block molecular entity	19626
hydrogen molecular entity	19613
hydrides	19115
inorganic hydride	18121
pnictogen hydride	18110
nitrogen hydride	18017
ammonium	8317
ammonium ion derivative	8291
quaternary ammonium ion	5287
quaternary nitrogen compound	876
LSM-5686	0
ammonium betaine +	367
iminium betaine +	56
nitrilium betaine +	0
quaternary ammonium salt +	551

paths to the root